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ABSTRACT 
 
Histone acetyltransferases (HATs) are important enzymes in transcriptional control and 
potential targets for chemotherapeutic intervention in malignant diseases. Among different HAT 
members, the yeast Esa1 and human Tip60 (the HIV-1 Tat interactive protein, 60KDa) play 
multiple roles in normal cellular processes including transcription, cell cycle and checkpoint 
machinery, double strand DNA break repair, apoptosis, and cell cycle progression. Tip60 is also 
implicated in several human diseases such as prostate cancer, and gastric cancer. These studies 
suggest that Tip60 is a potential therapeutic target for new cancer treatment. So, we designed 
experimental work to synthesize and investigate organic inhibitors of Tip60 using different 
strategies, including substrate analogs, small molecule screening, and modification of the natural 
product anacardic acid. These studies provide important chemical agents for basic biology 
research of HAT function, and produce potential lead compounds for future pharmacologic 
intervention of HAT deregulation in cancer.  
 Currently, of the methods used for the measurement of acetyltransferase activities, many 
comprise tedious separation procedures and involve enzyme-coupled steps or radioactive 
materials. These shortcomings have limited their applications in high-throughput screening 
(HTS) of HAT inhibitors. To circumvent these problems, a homogenous fluorescent HAT assay 
based on engineered H4 peptide was designed, synthesized, and evaluated. The data showed that 
these fluorescent reporters can be used to detect the acetyltransferase activities. 
 
INDEX WORDS: Histone acetyltransferases, Tip60, Substrate-based analogs, Virtual screening, 
Computer modeling, Fluorescent reporters 
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CHAPTER 1 
Introduction 
1.1. The structure and function of chromatin 
In eukaryotic chromosomes, DNA (145-147 base pairs) is packed on the histone proteins 
(H3, H4, H2A and H2B) to form a fundamental repeating genetic element called nucleosome. 
The nucleosome is a small unit of chromatin to store genetic information in the nucleus of each 
eukaryotic cell. Nucleosomes are linked by H1 protein to create highly compressed structures 
named chromatin fibers (Figure 1.1).1-3 This fiber, which has a “beads-on-string” fashion is 
around 30 nanometer, can be further coiled to chromosome regulating various nuclear process 
such as gene transcription, DNA replication and repair, mitosis and apoptosis.4 The chromatin 
structure can be changed by families of chromatin-modifying enzymes during different phases of 
cell division.5-8  
 
Figure 1.1. The structure of chromatin 
1.2. Characterization of histone modification  
Many sites modified on histone are detected by specific antibodies or mass 
spectrometry.9 Figure1.2 shows the diverse covalent modifications on histone tail domains.  
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These modification sites represent enormous potential biological functions (Table 1.1).10 For 
example, the residue Lys or Arg can be marked with methyl group in at last three different ways 
by varies methyltransferases: mono-, di-, or trimethyl for Lys and mono-, di- (asymmetric or 
symmetric) methyl for Arg.11, 12 Interestingly, the selectivity of methylation can lead to reverse 
biological functions, like histone H3 Lys 4 or Lys 27 methylation (mono-, di-, or tri-) can 
activate transcription, but H3 Lys 9 methylation (di-or tri-) causes transcriptional repression.13 
  
Figure 1.2. Post-translational covalent modifications of histone protein tail domains 
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Table 1.1. Different classes of histone modifications 
Histone 
modifications 
Amino acid 
residue 
Function Regulated Enzyme (Example) 
Methylation Lys, Arg Transcription, Repair PRMT114 
Acetylation Lys Transcription, Repair Tip6015 
Phosphorylation Ser, Thr Transcription, Repair MSK116 
Ubiqutylation Lys Transcription, Repair E117 
Sumoylation Lys Transcription SAE1/SAE218 
 
1.3. Histone acetylation and deacetylation 
Acetylation is one of the most important post-translational modifications on core histone 
tail domains. Chemically, the acetyl group can be transferred to ε-amino group of a target Lys 
residue by enzymatic reaction. In this reaction, acetyl-coenzyme A (AcCoA) is employed as 
acetyl group donor and acetyl-Lys and CoASH are final products. Conversely, removing the 
acetyl group from acetylated-Lys on histone is termed deacetylation. Histone acetylation and 
deacetylation regulate gene transcription: the former one acts as an activator and the latter one as 
a repressor. The balance between histone acetylation and deacetylation is influenced by two 
different enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs).19-21 
The mechanism of gene regulation affected by histone acetylation/deacetylation could be 
explained by charge hypothesis which asserts that the neutralization of positive charge on Lys 
residues can decrease the binding affinity between DNA and histone and vice versa.22, 23 Another 
theory, “histone code” hypothesis, proposes acetylation/deacetylation as special markers could 
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be recognized by other proteins or factors to initiate the transcriptional activation or repression 
(Scheme 1.1).24-26 
 
 
 
 
 
 
 
 
 
Scheme 1.1. Epigenetic control of gene transcription by histone acetylation 
1.4. Histone acetyltransferases (HATs)  
Histone acetyltransferases are grouped in several subfamilies based on a high sequence 
similarity.27 Furthermore, different HATs have their own substrates preference (Table 1.2) and 
share different catalytic mechanisms. Three different catalytic mechanisms have been reported 
during last ten years. For example, GCN5 family employs the sequential mechanism to build a 
ternary protein-AcCoA-substrate complex using a key amino acid Glu. Glu acts as a nucleophilic 
reagent to attack carbonyl group on AcCoA (Figure 1.3 A);28, 29 Esa1p from the MYST family 
(named after its founding members, MOZ, YBF2/SAS3, SAS2 and Tip60), utilizes a ping-pong 
mechanism to form a covalent intermediate (Ac-Cys) with a conserved Cys residue and transfer 
acetyl from Cys to target Lys (Figure 1.3 B);30 p300 catalyzes histone acetylation with a “hit and 
run” mechanism (Theorell–Chance acetyl transfer mechanism) (Figure 1.3 C).31 Other than 
lysine acetylation, HATs can also regulate their own HAT activities by autoacetylation. 
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Specifically, the loop’s hyperacetylation of p300 has been reported to enhance its HAT activity 
in vitro and in vivo,32 and Tip60 autoacetylation can be a significant step to control its HAT 
activity and function in response to DNA damage.33 
Table 1.2. Selected HAT families and key members34, 35 
HAT Organism Substrate specificity Function 
GNAT Family 
GCN5 Human H3(K9, K14, K18) Coactivator 
PCAF Human H3(K9, K14, K18) Coactivator 
CBP/p300 Family 
p300 Worm, 
human 
H3 (K14, K18)/ H4 (K5, K8) 
H2A (K5)/H2B (K12, K15) 
Global coactivator 
MYST Family 
MOZ Human H3 (K14) Coactivator 
Ybf2/Sas3 Yeast H3 (K14, K23) Elongation 
Sas2 Yeast H4 (K16) Silencing 
Tip60 Human H4 (K5, K8, K12, K16) 
H3 (K14)/H2A (K5) 
DNA-repair, apoptosis 
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 (A) GCN5 
 
(B) Esa1 
 
(C) p300 
 
Figure 1.3 Proposed kinetic and catalytic mechanisms of histone acetyltransferases 
1.5. Histone acetyltransferases Tip60  
Tip60 (tat interact protein 60 kDa), one of the key members in the MYST family, was 
originally reported as a co-activator for the HIV tat protein.29 Tip60 is located at chromosome 
11q13.1 and has 14 exons, which can splice to three most common variants: isoform 1, isoform 2 
and isoform 3 (Figure 1.4).36 All members of this family have a MYST domain of about 240 
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amino acids containing a canonical acetyl-CoA-binding site and C2HC-type zinc finger motif. 
Most MYST proteins also have a chromodomain involved in protein-protein interactions and 
targeting transcriptional regulators to chromatin.37 
 
 
 
 
 
 
Figure 1.4. The various isoforms of Tip60 protein domains. Isoform 2 is the well-studied 
Tip60 isoform 
Tip60 is an enzyme which can acetylate histone and non-histone protein, and plays 
multiple roles in affecting the functions of different targets in various biological pathways. For 
example, the mechanism for androgen receptor (AR) dependent prostate cancers suggested that 
Tip60 acts as an AR coactivator to form a ternary complex with histone deacetylase 1 (HDAC1) 
to regulate the activity of AR;38 In the cell cycle, the Mys family of transcription factors can 
regulate genes required for growth, DNA replication, and apoptosis.39, 40 Tip60 can acetylate c-
Myc and dramatically increase protein’s stability;41 Amyloid-β precursor protein (APP) is a 
transmembrane protein and one of several factors involved in Alzheimer’s disease. Tip60 can be 
recruited to form a complex with APP to co-activate gene promoters which may affect apoptosis 
and neurotoxicity;42-44 The transcription factor nuclear factor kappa light chain gene enhancer in 
B cell (NF-κB) affects immunity, inflammation, proliferation, and apoptosis. The activity of NF- 
κB can be regulated by its activator, Tip60.36  
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1.6. The study points in this work 
1.6.1. The inhibition study of Tip60 
The inhibition potency study of HATs in the past 10 years was divided into two fields. 
One is based on bisubstrate analogs, which covalently linked peptide or amino acid with CoA 
based on a ternary complex kinetic mechanism. The other one explores small molecules, 
including potential natural products, synthetic organic compounds or candidates from libraries 
which were identified by high-throughput enzymatic screening or virtual screening (Table 
1.3).45-61 Bisubstrate inhibitors showed strong inhibition for the HATs, for example, Lys-CoA for 
p300 (IC50 = 50 nM).45 But their high molecular weight, low cell permeability, and metabolic 
instability decrease their effectiveness in vivo.46 Small molecules have been discovered as HATs 
modulators. For example anacardic acid and its analogs have worked as inhibitors or activators 
for p300 and PCAF.47 But anacardic acid has no specificity to HATs.48 
The potential clinical impact of Tip60 inhibitors may be applicable to several types of 
cancer, like prostate cancer, colorectal cancer, and gastric cancer.49-53 However, the discovery of 
modulators for MYST family, especially for Tip60, has seen few reported. Thus, the 
development of regulators (inhibitor or activator) of Tip60 may provide us a way to understand 
the roles of Tip60 in biological pathways as well as give us a method to find the new therapeutic 
agents in curing cancers related to Tip60 acetylation. 
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Table 1.3. Known HAT modulators  
Chemical Name Modulation 
Lys-CoA IC50 = 50 nM (p300)45 
H3-CoA-20 IC50 = 3  μM (PCAF)45 
LysCoA-SS-R10 IC50 = 70 nM ( p300), IC50 = 25  μM (PCAF)54 
H3-CoA-20-TAT IC50 = 12 μM ( p300), IC50 = 40  nM (PCAF)55, 56 
Anacardic acid IC50 = 8.5 μM ( p300), IC50 = 5  μM (PCAF),47 IC50 = 9 μM (Tip60)57 
CTPB Increase HAT activity of p300 by 4 folds, but no effect PCAF47 
Garcinol IC50 = 7 μM ( p300), IC50 = 5  μM (PCAF)58 
LTK-13 IC50 = 5-7 μM ( p300)59 
LTK-14 IC50 = 5-7 μM ( p300)59 
LTK-19 IC50 = 5-7 μM ( p300)59 
CCT077791 IC50 = 7 μM ( PCAF)60 
Curcumin IC50 = 25 μM ( p300)61 
MB-3 IC50 = 500 μM ( CBP), IC50 = 100  μM (GCN5)62 
C646 Ki = 400 nM (p300)63 
C375 Ki = 4.8 μM (p300)63 
 
1.6.2. The development of HAT assays 
Modern drug discovery largely relies on high-throughput screening (HTS) methods to 
identify the potentially effective compounds.64 As seen in Table 1.4, several assays have been 
developed for monitoring HAT activity. Most commonly, radioactive materials labeled acetyl-
10 
 
 
group have been used as the target to be detected. These assays usually have higher sensitivity 
and quantization, but the drawback of this assay is the associated cost of disposal of radioactive 
waste. Homogeneous assays for acetylation have been reported (Table 1.4) and involve coupling 
enzymes or thiol sensors to assist the detection. However, the addition of other enzymes or 
sensors in these assays may affect the activity of HATs, lead to the side reactions, and give a 
signal which is not due to HAT acetylation. Thus, developing a usable HAT-HTS assay would 
greatly accelerate the rate of drug discovery for HATs and minimize the radioactive waste and 
side reactions. 
Table 1.4. Selected methods for measuring HAT activity 
Assay Detection system Advantages Disadvantages Suitable for 
HTS 
Filter binding45, 65-68 Radioactive Sensitivity Waste disposal  No 
SDS-PAGE1,69-71 Radioactive 
Phosphors image
Sensitivity Waste disposal No 
Production of CoA72 Fluorometric 
UV 
Continuous Dye reacts with 
thiol group 
No 
Enzyme-coupled assay73 UV Continuous Sensitivity Yes 
Streptavidin-coated beads 
coupled enzyme system74 
Radioactive 
 
Sensitivity 
Speed 
Cost Yes 
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1.6.3. The determination of IC50 in competitive binding assays 
The half maximal inhibitory concentration (IC50) is a parameter to study the effectiveness 
of a compound in blocking biological function.75 According to our case, IC50 represents the 
concentration of a compound which is required for half inhibition of HAT activity in vitro. 
In our HAT assay, a single concentration of radioligand AcCoA is used in every assay 
tube. Usually, the concentration of AcCoA should be used at or below its Km (Tip60) value. 
However, the lower concentration level of [14C]-AcCoA gives a lower detectable signal. In our 
study, 10 μM radioligand [14C]-AcCoA (appKm ~ 1 μM to Tip60) was used to study the inhibition 
of Tip60. At this condition, the ratio of signal/ noise can be controlled to 10 at the steady-state of 
enzyme inhibition, but the values of IC50 of target inhibitors were pretty high. Especially, we 
determined in the presence of a range of concentrations of other competitive non-radioactive 
compounds, in order to measure the potency with which they compete for the binding of the 
AcCoA. Competitive curves may also be fitted to the fractional activity equation (also described 
in chapter 2) which derived in scheme 1.2.  
Fractional activity = 1/(1 + [I]/IC50) 
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The system can be assumed at steady-state, which is when the concentration of each of enzyme 
species is stable. 
dE/dt = dES/dt = dEI/dt = 0         1 
dE/dt = -k1[E][S] + k-1[ES] + k2[ES] - k3[E][I] + k-3[EI] = 0     2 
dES/dt = k1[E][S] - k-1[ES] - k2[ES] = 0       3 
dEI/dt = k3[E][I] - k-3[EI] = 0         4 
(k-1+k2)/k1 = Km          5 
From equation 3, we can obtain:  
[E] = (k-1[ES] + k2[ES])/k1[S] = (Km[ES])/[S]      6 
(k-3)/k3 = Ki           7 
From equation 4, we can obtain:  
[EI] = k3[E][I]/k-3 = [E][I]/Ki = (Km[I][ES])/Ki[S]       8 
[E]T = [E] + [ES] + [EI] = (Km[ES])/[S] + [ES] + (Km[I][ES])/Ki[S]    9 
Rearranging eq 9 to solve for ES, we find: 
[ES] = [E]T[S]Ki/(KmKi + [S]Ki + [I]Km)       10 
The initial velocity is defined as:  
v = dP/dt = k2[ES]          11 
We can replace [ES] in eq 11 using eq 10, we now have: 
v = k2[ES] = k2[E]T[S]Ki/(KmKi + [S]Ki + [I]Km)      12 
We can replace k2[E]T with Vmax and combine terms to obtain the congenital form:  
v = k2[ES] = Vmax[S]/([S] + Km(1 + [I]/Ki))       13 
We wished to measure the IC50 value for an inhibitor on the enzymatic activity. Without the 
inhibitor, the velocity is described in eq 14: 
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v0 = Vmax[S]/([S] + Km)         14 
Thus the fractional activity and inhibition can be written as eq 15 and 16: 
v/v0 = ([S] + Km)/([S] + Km(1 + [I]/Ki))       15 
1 - v/v0 = [I]/([I] + Ki(1 + [S]/Km)        16 
To obtain the 50% inhibition, eq 16 should be equal to 0.5, we have: 
1 - v/v0 = [I]/([I] + Ki(1 + [S]/Km) = 0.5 
IC50 = [I]0.5 = Ki(1 + [S]/Km)         17 
We can use IC50 instead of [I]0.5 and rearrange eq 15. 
v/v0 = ([S] + Km)/([S] + Km(1 + [I]/Ki) ) 
v/v0 = ([S]/Km + 1)/([S]/Km + (1 + [I]/Ki) )       18 
Instead Ki(1 + [S]/Km) with IC50/Ki, we can get the final equation. 
Fractional activity = v/v0 = (IC50/Ki)/(IC50/Ki + [I]/Ki) = IC50/(IC50 + [I])  
Fractional activity = 1/(1 + [I]/IC50)        19 
Scheme 1.2. Derivation of IC50 equation in the competitive model  
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CHAPTER 2 
Bisubstrate Inhibitors of the MYST HATs Esa1 and Tip60 
(This work is mainly based on the published paper, Bioorg. Med. Chem. 17 (2009) 1381-1386. In 
this project, the author is obliged to Dr. Nan Xie, Dr. Zhikun Wu, Sabrina Asher, and Ying 
Zhang for their great contributions to prepare peptide compounds.) 
2.1. Introduction 
The lysine acetylation of core histones in eukaryotic chromatin is catalyzed by histone 
acetyltransferases (HATs). The acetylation elicits nucleosomal remodeling and chromatin 
structural relaxation which modulate many chromatin-associated nuclear processes such as gene 
transcription and DNA repair.76-79 HATs comprise of several distinct families based on sequence 
and structural homology,80-84 which include Gcn5/PCAF, the MYST family (named after its 
founding members, MOZ, YBF2/SAS3, SAS2 and Tip60);85 and the p300/CBP family. HAT 
proteins are not only essential to regulate gene expression in normal cellular processes (e.g. 
growth, differentiation, apoptosis), but malfunctioning of many HAT members, has also been 
observed in a range of disease states, especially cancer.81, 86-90 As such, chemical inhibitors or 
activators of HATs posses attractive pharmacological values in targeting the disease types that 
are regulated by dysfunctional acetylation. Indeed, recent years witnessed a surging effort of 
research to develop HAT inhibitors by various strategies.10, 91-93 Among these research 
endeavors, inhibitors of p300/CBP and PCAF/GCN5 have received considerable attention 
probably because they are considered robust HATs in mammalian cells and their enzymatic 
properties have been well characterized.31, 94-96 On the other hand, inhibitors of the MYST HATs 
are rarely reported. Anacardic acid, a weak and generic HAT inhibitor has been previously 
shown to inhibit the MYST HAT Tip60 and sensitize the tumor cells to the cytotoxic effects of 
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ionizing radiation.57 Given the essential roles of MYST HATs in normal cell function and 
pathogenesis, further effort (e.g. high-throughput screening or mechanism-based design) is 
needed to develop structurally diversified organic inhibitors to provide as selectable chemical 
tools for the mechanistic study of the HATs and as potential agents for pharmacological 
intervention. In this report, we present our work on designing bisubstrate analog inhibitors of 
Tip60 and its yeast orthologue Esa1. 
Tip60 and Esa1 share 70% of sequence homology and the well conserved MYST domain 
in the two proteins is responsible for the enzymatic acetylation activity. Tip60 has been reported 
to be involved in gene activation by a variety of transcription factors, such as c-Myc,41 E2F,97 
NF-κB,98 and p53,99-101 etc.36, 102 Tip60 participates in many important cellular processes, 
including apoptosis,101, 103 DNA repair,79, 103-107 developmental cell signaling,108 and ribosomal 
gene transcription.109 In particular, deregulation of Tip60 has been reported in certain human 
disease conditions,36, 88, 90, 107, 110, 111 including neurodegenerative disease,112-114 viral infection,51, 
115 and prostate cancer.116, 117 Therefore, new inhibitors with desirable potency and selectivity 
will be particularly useful in elucidating the functions of Tip60 and its role in disease.  
The use of bisubstrate strategy to design enzyme inhibitors has been applied in different 
systems, e.g., protein kinases118 and GNAT (general control nonrepressed factor 5-related N-
acetyltransferase) acetyltransferases.119 One of the very first examples of bisubstrate analogues is 
the proposition of a carnitine-CoA adduct that was involved in the self-catalyzed inactivation of 
carnitine acetyltransferase.120 Gentamicin- acetylCoA is another early example of bisubstrate 
analogue that inhibits the gentamicin N-acetyltransferase with nanomolar affinity.121 Early in the 
1980s, several polyamine-CoA conjugates were found to block HAT activity present in cellular 
extracts.122, 123 Cole and colleagues reported several indole-CoA bisubstrate analogues containing 
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different linkers that bind to serotonin N-acetyltransferase with nanomolar to submicromolar 
affinity.124, 125 The same group also synthesized bisubstrate HAT inhibitors, such as lysine-CoA 
for p300/CBP and histone H3 peptide-CoA analogues for PCAF/Gcn5.45, 126-128 More recently, 
AuClair et al129-131 designed and synthesized a series of 6'-N-acetylCoA bisubstrate analogues 
with nanomolar to micromolar potencies for the Enterococcus faecium aminoglycoside 6'-N-
acetyltransferase type Ii (AAC(6')-Ii). Some of these inhibitors have been applied in the kinetic 
and structural studies of AAC (6')-Ii and AAC (6')-Iy.129, 132 A priori, the rational design of 
bisubstrate inhibitors is better warranted if the target bireactant enzyme utilizes a sequential, 
ternary complex mechanism with either random or ordered substrate binding.119 Although the 
enzymatic mechanism of Esa1/Tip60 is still not yet completely resolved,30, 133 a recent study 
indeed showed features of ordered BiBi mechanism for the catalysis of Esa1.133 These points 
toward the possibility of developing bisubstrate analogs as Esa1/Tip60 inhibitors. 
2.2. Results and discussion 
2.2.1. Design and synthesis of the bisubstrate analog inhibitors 
Esa1 and Tip60 exhibit similar substrate specificity on histones. Recombinant Esa1 and 
Tip60 acetylate the amino-terminal tails of histones H2A, H3, and H4, but not H2B.134, 135 On 
chromatin, only H2A, H3, and H4 are acetylated by Tip60.102 Covalently, linking the coenzyme 
A substrate analog to the peptide substrate at the site of respective acetylated lysine residues, a 
series of bisubstrate analogs have been obtained as highly potent HAT inhibitors (Figure 2.1). 
Recombinant Esa1 and Tip60 were reported to acetylate up to six lysine residues on histones, i.e. 
K5 of H2A; K14 of H3; and K5, 8, 12, 16 of H4.135, 136 Based on such sequence and site 
specificity, we synthesized a series of bisubstrate analogs with CoASH covalently attached on 
each of the individual acetyl lysine residues in the histone peptides. The general synthetic route 
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followed solid-phase peptide synthesis first and then solution-phase coupling of CoASH to the 
peptides (Figure 2.2). To link CoASH with the side-chain of the lysine residue on the peptide, a 
bromoacetyl linker was introduced. All the compounds were purified by reverse-phased HPLC 
on a semi-preparative C18 column to a purity of higher than 95%. The sequence and mass 
spectrometric data are listed in Table 2.1, 2.2. Prior to the inhibition evaluation, the bisubstrate 
compounds were dissolved in water and sodium hydroxide was used to adjust pH to the neutral 
range. The concentration of each sample was determined based on the absorption of the CoA 
motif at 260 nm (Figure 2.3).  
N
H O
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Figure 2.1. General structures of the bisubstrate HAT inhibitors. The curly lines stand for 
amino acid sequence 
Ac-SGRGKGGKGLGKGGAKRHRK
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Figure 2.2. Synthetic schemes of bisubstrate analogs, H4K5CoA (1)  
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Figure 2.3. Concentration measurement of H4 (11-22)-CoA using absorbance at 260 nm 
Table 2.1. Sequences of the bisubstrate HAT inhibitors 
Name Sequence Expected mass Observed mass 
H4K5CoA (1) Ac-SGRGK (CoA) GGKGLGKGGAKRHRK 2840.9 2841.3 
H4K8CoA (2) Ac-SGRGKGGK (CoA) GLGKGGAKRHRK 2840.9 2841.2 
H4K12CoA (3) Ac-SGRGKGGKGLGK (CoA) GGAKRHRK 2840.9 2841.5 
H4K16CoA (4) Ac-SGRGKGGKGLGKGGAK (CoA) RHRK 2840.9 2841.3 
H2AK5CoA (5) Ac-SGRGK (CoA) QGGKARAKAKTRSSRA 3006.0 3007.3 
H3K14CoA (6) Ac-ARTKQTARKSTGGK (CoA) APRKQL 3036.4 3034.4 
Lys-CoA (7) Ac-Lys (CoA)-NH2 998.2 995.3 
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2.2.2. Organic reaction mechanisms of peptide synthesis 
2.2.2.1. HCTU coupling 
1H-Benzotriazolium 1-[bis(dimethyl-amino)methylene]-5-chloro-hexafluorophosphate 
(1-),3-oxide (HCTU) is a non-toxic, non-irritating, aminium-based and non-corrosive coupling 
reagent, analogous to HBTU. It was shown that HCTU can be used as an efficient coupling 
reagent for fast Fmoc solid-phase peptide synthesis.137 Scheme 2.1 shows the detailed 
mechanism of coupling reaction. The acid 1 will react with HCTU to produce the key 
intermediate 2, which can form compound 4 with an activated leaving group and compound 3. 
Compound 3 can react with compound 4 to form an important intermediate 5 and give another 
compound 6 with an activated leaving group. A designed compound 8 with an amine group can 
attach to compound 6, generating the intermediate 9, which will form the product 10 and 
compound 3.  
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Scheme 2.1. The mechanism of HCTU coupling reaction 
2.2.2.2. DIC coupling 
N, N'-diisopropylcarbodiimide (DIC) was one of the carbodiimides which can be used for 
amide and ester formation, especially for solid-phase peptide synthesis.138 Scheme 2.2 shows the 
detailed mechanism of coupling reaction. The acid 1 will react with the carbodiimide to produce 
the key intermediate 5, which can be used as a carboxylic ester with an activated leaving group. 
Compound 5 can react with an amine group to form a desired amide 8 and urea 7 though an 
important intermediate 6. 
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Scheme 2.2. The mechanism of DIC coupling reaction 
2.2.2.3. Fmoc deprotection 
9H-fluoren-9-ylmethoxycarbonyl (Fmoc) is a widely used protective group which can be 
removed by piperidine from the N terminus of a peptide in the solid phase peptide synthesis.139, 
140 Scheme 2.3 shows the detailed mechanism of Fmoc deprotection. The secondary amine group 
for piperidine reacts with the hydrogen on the fluoren to form the intermediate 2. Intermediate 2 
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can convert to compounds 4 and 5. The compound 4 can react with piperidine again to release 
the final product 6 and compound 5 can form the compound 7 and carbon dioxide.  
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Scheme 2.3. The mechanism of Fmoc deprotection reaction 
2.2.2.4. Dde deprotection 
N-(1-(4, 4-dimethyl-2, 6-dioxocyclohexylidene) ethyl) (Dde) is a widely used amine 
protective group which can be removed by hydrazine selectively. Scheme 2.4 shows the detailed 
mechanism of Dde deprotection. The amine group on the hydrazine can react with Dde to form 
the intermediate 2 which quickly release the protected amine group and form the compound 3. 
The compound 3 can suffer the intermolecular reaction to generate the compound 6 as the side 
product. 
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Scheme 2.4. The mechanism of Dde deprotection reaction 
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Table 2.2. Sequences of H4K16CoA compounds 
 Sequence Expected mass Observed mass
Ac-H4(15-17)-CoA-NH2 Ac-AK(CoA)R 1220.0 1223 
Ac-H4(14-18)-CoA-NH2 Ac-GAK (CoA) RH 1414.2 1416.6 
Ac-H4-(11-22)-CoA-OH Ac-GKGGAK (CoA)RHRKVL 2155.2 2156.0 
 
2.2.3. Inhibition of Esa1 and Tip60 by the bisubstrate analogs 
With those bisubstrate compounds in hand, we studied their inhibitory effect on the Esa1- 
and Tip60-catalyzed HAT reaction. The HAT reaction was performed using recombinant Esa1 
and Tip60 enzymes expressed from E. coli. [14C]-labeled acetyl-CoA and a peptide 
corresponding to the amino-terminal 20 amino acids of histone H4 (H4-20) were used as HAT 
substrates. Reactions were initiated with each enzyme after the other components were incubated 
at 30 °C for 5 min. The reaction was quenched by loading the mixtures onto the surface of a P81 
filter paper disc. After washing and drying the paper, liquid scintillation was used to quantify the 
amount of product. 
To quantitatively analyze the inhibition, we conducted the HAT reaction at a range of 
concentrations of individual inhibitors. A typical inhibition curve is shown in Figure 2.4. The 
data were fitted to the Langmuir isotherm equation (equation 1) to obtain the IC50 values of the 
inhibitors. The inhibition data of the tested compounds are summarized in Table 2.3.  
Fractional activity = 1/(1 + [I]/IC50)        (1) 
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Figure 2.4. Inhibition of Tip60 by H4K16CoA (4). The HAT reaction solution contains 100 
nM of Tip60, 10 μM of 14AcCoA, and 200 μM of H4-20. 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
Table 2.3. IC50 of the tested inhibitors for different HATs. HAT reaction conditions 
employed 50 nM Esa1, 60 μM H4-20, 10 μM 14AcCoA; 5 nM p300, 60 μM H4-20, 10 μM 
14AcCoA; 100 nM Tip60, 200 μM H4-20, 10 μM 14AcCoA; 5 nM PCAF, 60 μM H3-31, 10 
μM 14AcCoA. 
 Esa1 (μM) Tip60 (μM) p300 (μM) PCAF (μM) 
H4K5CoA (1) 18.33 ± 1.07 143.35 ± 21.70 2.88 ± 0.46 65.93 ± 6.41 
H4K8CoA (2) 13.94 ± 2.36 111.70 ± 19.24 8.15 ± 0.70 124.30 ± 13.61 
H4K12CoA (3) 20.30 ± 2.70 25.87 ± 8.09 4.35 ± 0.39 53.57 ± 9.83 
H4K16CoA (4) 5.51 ± 0.98 17.59 ± 2.40 6.62 ± 0.56 58.47 ± 4.22 
H2AK5CoA (5) 12.09 ± 0.30 20.91 ± 2.48 17.35 ± 1.39 60.54 ± 2.96 
H3K14CoA (6) 4.78 ± 1.05 79.62 ± 17.22 7.54 ± 1.15 2.27 ± 0.14 
Lys-CoA (7) 7.00 ± 1.18 29.75 ± 2.88 0.98 ± 0.01 108.30 ± 6.73 
CoASH 68.58 ± 8.07 82.27 ± 16.25 45.94 ± 6.92 41.91 ± 4.20 
Curcumin >40 >200 >40 -------- 
Anacardic acid 297.23 ± 96.078 347.59 ± 55.39 >1000 667.05 ± 349.51 
 
From the inhibition experiments, it is clear that different bisubstrate analogs inhibit Esa1 
and Tip60 with varied magnitudes of potency. The IC50 values of the bisubstrate analogs are in 
the range of 4.8~20 μM for Esa1 and 17.3~143 μM for Tip60. The difference in the inhibitory 
potency of these bisubstrate analogs for either Esa1 or Tip60 indicates that the amino acid 
sequences flanking the CoA-attaching site can impact the binding affinity of individual 
compounds to the HAT enzyme. Interestingly, the potency of the analog inhibitors is not 
restrictedly in line with the substrate and site specificity of Esa1 and Tip60. For example, both 
Esa1 and Tip60 were reported to favorably acetylate H4K5 and H4K8 and H2AK5;135, 136 
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nevertheless, H4K5CoA (1) and H4K8CoA (2) and H2AK5CoA (5) are shown here not to be the 
strongest inhibitors. Instead, the compound H4K16CoA (4) is shown to be a potent inhibitor for 
both Esa1 and Tip60, with IC50 value of 5.5 and 17.3 μM, respectively (in addition, Esa1 can 
also be inhibited effectively by H3K14CoA (6) with an IC50 of 4.8 μM). These data suggest that 
H4-K16 may also be a quite favorable acetylation site by Esa1 and Tip60. Further biochemical 
study is needed to address this hypothesis. As seen from Table 2.3, the IC50 values of the tested 
analogs for Tip60 are generally higher than for Esa1, the reason of which is not clear at this stage 
but may be associated with certain conformational differences in the free recombinant forms of 
the two enzymes. 
We also compared the inhibitory potency of the bisubstrate analogs with curcumin and 
anacardic acid, two previously reported small-molecule generic HAT inhibitors. In particular, 
anacardic acid has been previously shown to inhibit the HAT activity of Tip60.57 As shown in 
Table 2.3, all the tested bisubstrate analogs are much more potent HAT inhibitors than the two 
small molecules. Notably, H4K16CoA (4) is 20 fold more potent than anacardic acid in 
inhibiting the HAT activity of Tip60 and 50 fold more potent in inhibiting Esa1. It is worthwhile 
to point out that the measured IC50 value of anacardic acid here (347 μM) for Tip60 is much 
higher than the literature value (9 μM).57 The difference is likely because in our experiments the 
purified recombinant enzymes and radioactive assay were used, but an ELISA assay (Enzyme-
linked immunosorbent assay) on immunoprecipitated Tip60 from HeLa cell extracts was used in 
the previous study. It is known that IC50 is a relative parameter in evaluating potency of enzyme 
inhibitors, and it largely depends on practical experimental conditions such as assay protocol, 
type of signal readouts, enzyme resources, substrate concentrations, temperature, etc. In our 
experiment, curcumin is also a weaker HAT inhibitor than the bisubstrate compounds, but due to 
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its poor aqueous solubility—less than 1 mM in 10% DMSO/water, the IC50 data cannot be 
accurately assessed. The much stronger potency of the bisubstrate analogs compared to the small 
molecule HAT inhibitors strongly highlights the effectiveness of the bisubstrate strategy in 
designing HAT inhibitors. 
2.2.4. Inhibition pattern of the bisubstrate analog H4K16CoA (4) 
We further tested whether the bisubstrate compounds are competitive or noncompetitive 
inhibitors versus the HAT substrates. This information will be useful to calculate the Ki of the 
designed HAT inhibitors and may also provide mechanistic insight into the enzymatic 
mechanisms of the HATs. Since H4K16CoA (4) exhibited a high potency for both Esa1 and 
Tip60, we examined its inhibition pattern. First, the kinetic parameters of Esa1 were measured 
and are as follows: kcat = 44.1 ± 2.6 min-1, KH4-20 = 220.2 ± 25.4 μM, and KAcCoA = 3.51 ± 1.80 
μM. For inhibition pattern study, we measured the initial velocity of Esa1 against either acetyl-
CoA or H4-20 at a fixed, unsaturating concentration of the other substrate and several selected 
concentrations of H4K16CoA (4). The primary double reciprocal plots with E/V versus 1[acetyl-
CoA] and E/V versus 1/[H4-20] identify the intersecting points on and to the left of the ordinate, 
respectively (Figure 2.5). Such a pattern characterizes that H4K16CoA (4) is a competitive 
inhibitor as to acetyl-CoA, and a noncompetitive inhibitor as to the H4 peptide substrate. The 
inhibition kinetic data points were also fitted to the nonlinear competitive or noncompetitive 
inhibition equations (equation 2 and 3).141 The apparent Ki determined from the competitive 
pattern versus AcCoA is 0.74 ± 0.13 μM, and the noncompetitive inhibition versus H4-20 yields 
Kis of 12.02 ± 4.16 μM and Kii of 9.27 ± 3.20 μM. Our study of Esa1 inhibition by H4K16CoA 
(4) most likely suggests an ordered substrate binding with acetyl-CoA binding to Esa1 first, 
followed by the peptide substrate binding.119 This agrees well with the reported models of Esa1 
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catalysis.30, 133 Previously, it was shown that H3CoA20 (referred to as compound 6, H3K14CoA 
here) is competitive versus acetyl-CoA and noncompetitive versus the histone substrates in the 
analysis of PCAF.96 Hence, it is likely a general feature that the bisubstrate inhibitors of HATs 
are competitive versus the acetyl-CoA, and noncompetitive versus protein substrates. 
 
 
 
 
 
 
 
 
 
Figure 2.5. Steady-state kinetic analysis of H4K16CoA in the inhibition of Esa1 A. E/V 
versus 1/ [acetyl-CoA] at fixed H4-20 peptide substrate concentration (200 μM) and 
varying H4K16CoA: 0 μM (♦), 5 μM (■), 20 μM ( ). B, E/V versus 1/ [H4-20] at fixed 
acetyl-CoA concentration (10 μM) and varying H4K16CoA: 0 μM (♦), 5 μM (■), 10 μM (
). 
2.2.5. Structure-activity relationship (SAR) of bisubstrate compounds in Tip60 inhibition 
Figure 2.2 showed the synthetic method to obtain the CoA-peptide bisubstrate inhibitors. 
Based on the previous data, one of best acetylation sites may locate in K16. According to H4 tail 
domain, we selected 5 different peptide lengths related K16 position. The HAT inhibition assay 
for Tip60 was tested and expressed in the form of IC50 values. From Lys-CoA to H4-20-CoA, the 
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result indicated that the inhibition potency of the bisubstrate inhibitors may not be change with 
various peptide chains (Figure 2.6).  The possible reason for the weak effect of length of peptide 
chain may be the low binding affinity between Tip60 and peptide (Km H4-20 around 500 µM).  
 
Figure 2.6. IC50 (μM) of the compounds tested for the development inhibitors forTip60. The 
HAT reactions were carried out with 10 μM of 14AcCoA, 100 μM of H4-20, and 100 nM of 
Tip60. 
To examine which groups observed in active site may contribute more in the catalysis of 
the enzymatic reaction. The groups named 3'-phosphate-adenosin and diphosphates were deleted 
and only pantetheine was attached to H4-K16 peptides (more details will be discussed in chapter 
3). The data were shown the inhibitory activity of H4-pantetheine dramatically decreased in the 
absence of 3'-phosphate-adenosin and diphosphates. This result was consistent with previous 
report which the Lys-pantethine was no detectable p300 HAT inhibition.142 
In summary, the use of bisubstrates strategy to design enzyme inhibitors has been well 
documented in the literature. Cole and coworkers are among the first to design HAT inhibitors 
IC50 
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by using the bisubstrates strategy.45 From their work, two substrate-based analogs, H3K14CoA 
(6) and Lys-CoA (7) were found to be potent and selective inhibitors for PCAF and p300, 
respectively, and have been used widely as technical tools in studying functions and structures of 
HATs in different biological contexts.126 Our experiments confirmed some of the previously 
reported features of H3K14CoA (6) and Lys-CoA (7). For example, Lys-CoA (7), amongst all 
the tested compounds, is particularly selective for p300 when compared to Esa1, Tip60, and 
PCAF. The compound H3K14CoA (6) is most potent for PCAF, which is likely due to the fact 
that H3K14 is a favorable acetylation site for PCAF.67 A minor notion is that H3K14CoA (6) can 
also block Esa1 activity with a fairly low value of IC50 (4.8 μM). Thus, if one is to use 
H3K14CoA (6) to study GCN5 function in yeast, caution need be taken due to its impact on the 
activity of Esa1. Similarly, although H4K16CoA (4) presents nice inhibition of the activities of 
Esa1 and Tip60, its inhibitory effect on p300 should not be neglected. 
Prior to this report, it has remained an unknown question whether bisubstrate inhibitors 
can be developed for the MYST family of HATs. The bisubstrate strategy is presumably feasible 
when the enzyme of study follows a ternary complex model in catalysis. This feature is 
particularly true for the GNAT superfamily acetyltransferases, for which many members have 
been reported to be effectively inhibited by covalent bisubstrate analogues.119 Structural 
homology analysis suggests that Esa1 may also belong to the GNAT superfamily,80 and a recent 
kinetic study offers evidence of ternary complex mechanism for the Esa1 catalysis.133 Our data 
successfully demonstrate that bisubstrate analogs can be made for the inhibition of Esa1/Tip60 
with a much higher potency than the previously reported small molecule HAT inhibitors. 
Notably, the inhibition of Tip60 by H4K16CoA (4) is 20-fold more potent than anacardic acid 
(Table 2.4). In addition, we showed that the inhibition of Esa1 by H4K16CoA (4) is linearly 
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competitive against acetyl-CoA and noncompetitive against the peptide substrate, which support 
an ordered substrate binding mechanism. 
It is well known that chemical inhibitors and activators are powerful mechanistic tools for 
investigating mechanisms and functions of enzymes in vitro and in vivo.118, 143 In particular, 
bisubstrate analogues can be applied as diagnostic probes to investigate enzyme kinetic 
mechanisms.119 Also, bisubstrate analogs have been demonstrated to be binding ligands for the 
structural characterization of target enzymes to examine amino acid residues involved in 
substrate recognition and catalysis.128, 132, 144 Although the bisubstrate compounds shown here 
might be limited to in vitro use and presumably are not cell-permeable owing to the anionic 
nature of the CoA motif, the limit can be overcome by applying different strategies, e.g., by 
linking with a cell-permeable sequence such as the TAT transduction domain.145, 146 Together, 
the analogs reported here will be useful biochemical probes to define the kinetic mechanisms of 
HATs, dissect the relative roles of MYST HATs in protein acetylation and transcription, and 
serve as affinity ligands for protein crystallization and structural determination. 
In SAR study, a series of bisubstrate inhibitors with different peptide length were 
synthesized and evaluated. The peptide conjugated CoA moiety gave a high inhibitory potency to 
the HAT activity of Tip60 (IC50 ~ 25 µM). The most contribution to block the HAT activity of 
Tip60 came from CoA motif, specially, from adenosine 3'-phosphoate- 5'-diphosphates.  
2.3. Conclusion 
We designed and synthesized a series of bisubstrate analogs for the inhibition of MYST 
HATs Esa1 and Tip60. Enzymatic assays showed that these bisubstrate analogs are much more 
potent than small molecules curcumin and anacardic acid. In particular, H4K16CoA (4) was 
tested as one of the most potent inhibitors for both Esa1 and Tip60, and the inhibition is 
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competive versus acetyl-CoA and noncompetitive versus the histone H4 substrate. It is expected 
that these new bisubstrate inhibitors will find use in the mechanistic and structural studies of 
Esa1, Tip60 and other MYST HATs. An effective unit (adenosine 3'-phosphoate-5'-
diphosphates) of bisubstrate inhibitors was comfirmed by SAR study. This information may give 
us a clue to design the small molecule inhibitors. 
2.4. Experimental 
2.4.1. Synthesis of the bisubstrate inhibitors 
Solid Phase peptide synthesis (SPPS) was performed on a PS3 synthesizer using the 
Fmoc [N-(9-fluorenyl) methoxycarbonyl] strategy. Pre-loaded Wang resins were used as the 
solid phase. For the coupling of each amino acid (AA), HBTU [2-(1H-Benzotriazole-1-yl)-1, 1, 
3, 3-tetramethyluronium hexafluorophosphate] and HOBt (N-Hydroxybenzotriazole) were used 
as activating reagents. Removal of Fmoc group was performed with 20% v/v piperidine/DMF. 
The N-terminal amino group was acetylated with acetic anhydride. After all the amino acids 
were coupled to the solid phase, the Dde group (dimethyldioxocyclohexylidene) was removed 
with 2% hydrazine in DMF for 2 h. The resin was then treated with 10 eq. of BrCH2COOH and 
10 eq. of DIC (N, N'-Diisopropylcarbodiimide) in DMF for 4 h. After washing and drying in 
vacuum, the bromo-labeled peptides were cleaved from the resin by treatment with 95% TFA, 
2.5% H2O, and 2.5% triisopropylsilane for 4 h. Crude products were precipitated with cold ether, 
and then purified with reverse-phased HPLC. All the bromopeptide products were characterized 
with analytical HPLC and MALDI-MS before the next-step reaction. To linking CoASH to the 
peptide, a mixture of 1 eq. bromopeptide and 2 eq. CoASH was dissolved in a minimum amount 
of sodium phosphate buffer (100 mM, pH 8). The mixture was allowed to stand in the dark for 
16 h. The final bisubstrate products were purified with reverse-phased (RP) HPLC (C18, Varian) 
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on a Varian Prostar HPLC system using linear gradients of H2O/0.05% TFA (solvent A) vs. 
acetonitrile/0.05% TFA (solvent B). Analytical HPLC and MALDI-MS were used for 
characterization. The purified inhibitors were dissolved in ddH2O and adjusted to neural pH 
using NaOH. The concentrations of the inhibitor solutions (peptide-CoA) were determined by 
UV absorption at 260 nm (extinction coefficient = 16045M-1cm-1). 
2.4.2. Expression of HAT enzymes 
Recombinant p300 protein was a gift from Dr. Philip Cole, and all the other HATs were 
expressed in our lab. His6x-tagged recombinant Esa1 (105-445) and full-length Tip60 alpha 
were expressed in E. coli and purified on metal affinity beads. In a typical procedure, the Esa1 
(105-445)-pRSETB plasmid was transformed into E. coli BL21codon plus (DE3)-RIPL 
(Stratagene), the Tip60 (1-513)-pET15b plasmid was transformed into BL21(DE3), and PCAF 
HAT domain (493-658) in a pET28a vector was transformed into BL21(DE3) codon plus cells, 
using heat shock method. Protein expression was induced with 0.6-mM IPTG at 16 °C for 20 h. 
After protein expression, cells were pelleted by centrifuge; suspended in the lysis buffer (25 mM 
HEPES pH 8.0, 500 mM NaCl, 1 mM PMSF, 1 mM MgSO4, and 10% glycerol) and lysed by 
sonification or French Press. The protein supernatant was purified on the Ni-charged His6x-tag 
binding resin (Novagen). Before protein loading, the beads were equilibrated with a column 
buffer (25 mM Na-HEPES, pH 8.0, 300 mM NaCl, 1 mM PMSF, and 30 mM imidazole). After 
protein loading, the beads were washed thoroughly with the column buffer, and then the protein 
was eluted with the elution buffer (25 mM Na-HEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF, 100 
mM EDTA, and 200 mM imidazole). Different elution fractions were checked on SDS-PAGE. 
Then, protein fractions were combined and dialyzed against the storage buffer (25 mM Na-
HEPES, pH 7.0, 500 mM NaCl, 1 mM EDTA, 10 mM DTT, and 10% glycerol) at 4 °C.  After 
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dialysis, the protein solution was concentrated using Millipore centrifugal filters. The final 
protein samples were alliquoted, flash-frozen, and stored in a -80 °C freezer. 
2.4.3. Enzymatic HAT assay 
Radioisotope-labeled HAT assay was carried out at 30 °C in a reaction volume of 30 μL. 
The reaction buffer contained 50 mM HEPES at pH 8.0, 0.1 mM EDTA, BSA 50 μg/mL, and 1 
mM dithiothreitol. Typically, [14C]-labeled acetyl-CoA (GE Healthcare) was used as the acetyl 
donor and a peptide containing the N-terminal 20-amino acid sequence of histone H4 (H4-20) 
was used as the HAT substrate. To determine the IC50 values, a range of at least seven inhibitor 
concentrations varied at least 20-fold around the IC50 were used. The reaction was initiated with 
the HAT enzyme after the other components (acetyl-CoA, H4-20, and the inhibitor) were 
equilibrated at 30 °C for 5 min. Rate measurements were based on initial conditions (generally 
less than 10% consumption of the limiting substrate). After the reaction, the mixture was loaded 
onto a Waterman P81 filter paper and then washed with 50 mM of sodium bicarbonate (pH  9.0) 
for three times. The paper was air dried and the amount of radioactivity incorporated into the 
peptide substrate was quantified by liquid scintillation. In all cases, background acetylation (in 
the absence of enzyme) was subtracted from the total signal. The IC50 was obtained from the plot 
of fractional HAT activity versus inhibitor concentration using the Langmuir isotherm equation 
(1). All the assays were performed at least twice, and duplicates generally agreed within 20%. 
The inhibition pattern of the bisubstrate inhibitor H4K16CoA (4) was determined by 
measuring initial velocities of Esa1 at different concentration of one substrate, a fixed 
concentration of the second substrate, and selected concentrations of H4K16CoA (4). The data 
were fitted to equations (2) and (3) which describe linear competitive and noncompetitive 
inhibition, respectively. 
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v = V[A]/([A] + Ka(1 + [IA-B]/Kis))        (2) 
v = V[A]/([A](1 + [IA-B]/Kii) + Ka(1 + [IA-B]/Kis))      (3) 
where v is the measured initial reaction velocity, V is the maximal velocity (in the absence of 
inhibitor), [A] is the concentration of the varied substrate, Ka is the corresponding apparent 
Michaelis-Menten constant, [IA-B] is the concentration of the bisubstrate inhibitor, and Kis and Kii 
are the slope and intercept inhibition constants, respectively. 
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CHAPTER 3 
Synthesis of H4 pantetheine adducts for histone acetyltransferase inhibition 
(This work is mainly based on the published paper, Heterocycl. Commun. In press) 
3.1. Introduction 
Histone acetyltransferases (HATs) catalyze the lysine acetylation on the core histones in 
eukaryotic chromatin. Histone acetylation is linked to gene transcription, DNA repair and 
associated with several diseases, especially cancer.19-21, 24-26, 38 Chemical inhibitors of HATs have 
been developed by different strategies and applied both as chemical probes and as potential 
anticancer therapeutics.91, 92, 147 Recently, bisubstrate inhibitors were synthesized and indicated 
strong inhibition to HATs, such as Lys-CoA for p30045 and H4K16-CoA for Tip60.147 However, 
the negatively charged phosphate groups in the CoA motif cause poor pharmacokinetics 
performance and restrict their applications in vivo.142 The CoA precursor called pantetheine was 
shown to exhibit good ability of penetrating the cell membrane and can be transformed to CoA 
by the endogenous CoA metabolic pathway (Figure 3.1).148 This advantage encourages us to 
synthesize histone peptide K-pantetheine analogs which could be used to study inhibition of 
HATs, especially in vivo.  
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Figure 3.1. Biological synthesis of CoA form its precursor pantetheine 
Solid phase Fmoc peptide chemistry was used to synthesize the chain of H4 peptide 
containing Dde (dimethyldioxocyclohexylidene) protecting group at N-ε-Lysine 16. An effective 
hydrazine deprotection step was recruited to release free primary amine on H4K16 which can 
react with bromoacetic acid to form amide bond. Two different methods (Figure 3.2) were 
studied to obtain H4K16-pantetheine. Although both strategies yielded the designed molecular 
mass peak on mass spectrometry, only directly conjugating pantetheine to H4K16 was confirmed 
as an effective route to create lysine-pantetheine modification on the tested peptides.  
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Figure 3.2. Synthesis of peptide K-pantetheine adducts through two strategies: 
hydrolysis of the peptide-CoA (A) and directly conjugating pantetheine to peptide (B). 
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3.2. Results and discussion 
3.2.1. Hydrolysis of peptide-CoA product precursor 
The structure of CoA has two phosphate groups between pantetheine and 3'-phosphate-
adenosine (Figure 3.2). The bond between phosphorus and oxygen of phosphate ester can be 
hydrolyzed by different methods.149, 150 Free H4-Br can be cleaved from resin by 95% TFA 
(Trifluoroacetic acid) solution at room temperature. This means the peptide backbone is stable in 
this condition. So, we attempted to hydrolyze H4 (11-22) K16-CoA with TFA at different 
volumes, reaction times and temperatures. The reaction was monitored by MALDI-MS. 
However, MS spectra always showed a major peak at 1728.9 Da or 1830.6 Da which 
corresponded to the fragment H4 (11-22) K16-pantetheine plus one phosphate or two 
phosphates) and the expected peak at 1666.9 Da as the minor one (Figure 3.3). The result 
indicated the leaving group is a key to control the direction of hydrolysis. Our result showed OR' 
(R' = adenosine 3'-phosphate 5'-monophosphate) is a much better leaving group than OR (R = 
pantetheine peptide) in TFA hydrolysis.  The phosphate ester bond between phosphate and H4 
(11-22) K16-pantetheine could be destroyed by stronger acidic condition or higher temperature. 
The harsh condition, however, may also break the peptide bond or the side chain of amino acid, 
driving hydrolysis reaction even more complicated. 
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Figure 3.3. Mass spectroscopic data of two synthetic methods (only the major peaks were 
shown). (A), (B), and (C) Hydrolysis of peptide-CoA product precursor in TFA (w/v = 1:20) 
at room temperature, 40 °C and 60 °C for 10 h. (D) Direct coupling of pantetheine to 
peptide at room temperature for 10 h. 
3.2.2. Direct coupling of pantetheine to peptide  
Pantetheine synthesized by its dimeric form pantethine has been reported.151, 152 DTT 
(dithiothreitol) has been used to reduce pantethine and the process of reaction was monitored by 
HPLC. The retention time for each component was 18 min for DTT, 22 min for pantetheine, and 
27 min for pantethine under the gradient 5 - 40% (buffer A and buffer B described in experiment 
section) (Figure 3.4A). The reaction finished within 10 h. After HPLC purification, glue-like 
product was obtained after lyophilization. ESI-MS (M + Na+) m/z is 301 (Calcd for 
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C11H22N2O4S: 278). 
 
Figure 3.4. HPLC analysis of coupling pantetheine to Lysine-Br. (A) The reaction mixture. 
(B) Lysine-pantetheine after purification (retention time: 23.0 min). 
The mechanism of conjugating pantetheine to peptide is a SN2 reaction. The pantetheine 
thiolate (pH 8) acts as a nucleophile to attack H4-Br (the electrophile), resulting in H4 
pantetheine, with bromide released as a leaving group. Because the weight of pantetheine is 
difficult to measure, the amount of pantetheine must be controlled carefully. Inappropriate 
amounts of pantetheine could complicate the purification process. From HPLC analysis, the 
product peak from the reaction largely overlapped with pantetheine if pantetheine was used up to 
5 equivalents (eq) of peptide. To resolve this issue, the quantification of pantetheine can be done 
by equally separating the solution made after redissovling glue-like pantetheine. Another issue is 
that the solution should be made freshly because thiol group is unstable under basic condition.  
Here, Table 3.1 lists MS information of four Lysine-pantetheine analogs synthesized with 
different peptide lengths. Based on these data, the results matched well with the expected values. 
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Table 3.1. Molecular mass of H4K16-pantetheine analogs  
 
3.2.3. Test of enzymatic inhibition 
Following the synthesis, we measured the activities of pantetheine and the peptide-
pantetheine compounds for their ability in blocking Tip60-catalyzed acetyltransferase reaction. 
The data showed that at 1 mM of concentration, most of these peptide-pantetheine compounds 
showed marginal inhibitory activities for Tip60 (Figure 3.5). As the peptide length becomes 
longer, the potency of inhibition becomes stronger. For example, H4 (11–22)-pantetheine has the 
longest length and shows the strongest potency, with 43% of Tip60 activity inhibited at 1 mM of 
this compound. Nevertheless, the overall potencies of these compounds are weaker than the 
peptide-CoA compounds that we reported previously.147 These results therefore demonstrate that 
adenosine pyrophosphate is an indispensable element to achieve high potency of HAT inhibition. 
 
 
 
 
 
Peptide-pantetheine Peptide Sequence Formula Calcd found 
Lys-pantetheine K C21H39N5O7S 505.6 505.2 
H4 (15-17) K16-pantetheine AKR C30H56N10O9S 732.9 733.3 
H4 (14-18) K16-pantetheine GAKRH C38H66N14O11S 927.1 927.4 
H4 (11-22) K16-pantetheine GKGGAKRHRKVL C71H129N26O18S 1667.0 1666.9 
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Figure 3.5. Activity of H4-pantetheine analogs for Tip60 inhibition. For the HAT assay, the 
reaction contained 200 μM of H4-20, 10 μM of 14AcCoA, and 100 nM of Tip60. The 
concentration of peptide-pantetheine analogs and pantetheine is 1 mM. (A. without 
inhibitor, B. pantetheine, C. Lys- pantetheine, D. H4 (15-17) K16- pantetheine, E. H4 (15-
18) K16– pantetheine, F. H4- (11-22) K16- pantetheine) 
3.3. Conclusion 
In this paper, we compared two methods of peptide-pantetheine synthesis: hydrolysis of 
the peptide-CoA and directly conjugating pantetheine to peptide. The second one showed an 
effective synthetic method to obtain lysine modification of peptide with pantetheine.   
3.4. Experimental 
3.4.1. Materials:  
Fmoc-L-amino acids, HCTU (2-(6-chloro-1H-benzotriazole-1-yl)-1, 1, 3, 3-
tetramethylaminium hexafluorophosphate), pre-loaded Wang resin, and Rink amide resin were 
purchased from Novabiochem. DIC (N, N'-diisopropylcarbodiimide), DMF 
(dimethylformamide), DCM (dichloromethane), TIS (triisopropylsilane), TFA, and ether were 
purchased from Fisher Scientific; DTT and pantethine were purchased from Sigma-Aldrich.  
3.4.2. Synthesis of bromopeptide 
Solid phase peptide synthesis (SPPS) was performed on a PS3 synthesizer using the 
Fmoc [N-(9-fluorenyl) methoxycarbonyl] strategy. Pre-loaded Wang or Rink amide resin was 
used. For the coupling of each amino acid (AA), HCTU was used as the activating reagent. 
Removal of Fmoc group was performed with 20% v/v piperidine/DMF. The N-terminal amino 
group was acetylated with acetic anhydride. After finished solid phase synthesis, Dde was 
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removed with 2% hydrazine in DMF for 2 h. The resin was then treated with 5 eq. of 
BrCH2COOH and 5 eq. of DIC in DMF for 4 h. After washing and drying in vacuum, the bromo-
labeled peptide was cleaved from the resin by treatment with 95% TFA, 2.5% H2O, and 2.5% 
TIS for 4 h. Crude products were precipitated with cold ether, and then purified with reverse-
phased HPLC. All the bromopeptide products were characterized with analytical HPLC and 
MALDI-MS before the next-step reaction.  
3.4.3. Directly conjugating pantetheine to peptide 
For the linkage of pantetheine to the bromopeptide, a mixture of 1 eq. bromopeptide and  
5 eq. pantetheine was dissolved in a minimum amount of sodium phosphate buffer (100 mM, pH 
8). The mixture was allowed to stand in the dark for 16 h. The final bisubstrate products were 
purified with reverse-phased (RP) HPLC (C18, Varian) on a Varian Prostar HPLC system using 
linear gradients of H2O/0.05% TFA (solvent A) versus acetonitrile/0.05% TFA (solvent B). 
Analytical HPLC and MALDI-MS were used for characterization. The purified analogs were 
dissolved in ddH2O and adjusted to neural pH using NaOH at 7.0.  
Pantetheine was synthesized by reducing pantethine (bis-pantetheine). The reaction 
contained 1eq. pantethine, and 5eq. DTT in 50 mM Tris buffer (pH 8.0). After 16 h, the mixture 
was centrifuged at 13000 rpm for 10 min. The supernatant was purified with reverse-phased 
HPLC system using linear gradients of H2O/0.05% TFA (solvent A) versus acetonitrile/0.05% 
TFA (solvent B). Analytical HPLC and MALDI-MS were used for characterization. 
3.4.4. Hydrolysis of peptide-CoA 
In the hydrolysis strategy, TFA was used to directly cleave the adenosine 3'-phosphate 5'-
diphosphate  from the CoA motif from peptide-CoA which was synthesized by similar method 
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(Scheme 3.1B).147 The reaction was studied by different time (2-16 h), temperature (25-60 °C), 
and amount of TFA. The mixture was dissolved in H2O and analyzed by MALDI-MS.  
3.4.5. HAT assay 
Radioactive acetyltransferase assays were conducted as previously reported.147 [14C]-
labeled acetyl-CoA was used as donor and the N-terminal 20 amino acids of histone H4 (H4-20) 
were used as HAT substrates. Recombinant Tip60 was expressed in BL21 (DE3) cells. 
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CHAPTER 4 
Small molecule inhibitors of histone acetyltransferase Tip60 
(This work is mainly based on the published paper, Bioorg. Chem. 39 (2011) 53-5. In this 
project, the author is obliged to Dr. Minyong Li, Dr. Binghe Wang, and Yutao Yang for their 
great computer technology support, to Dr. Juxian Wang for her assistance to the identification of 
small molecule inhibitors.) 
4.1. Introduction 
The 60-kDa HIV Tat-interacting protein (Tip60), one of key members of the MYST 
(MOZ, Ybf2/Sas3, Sas2, Tip60) family of histone acetyltransferases (HATs), was originally 
identified as an HIV-1 Tat associating protein by yeast two-hybrid screen.153 It catalyzes the 
transfer of acetyl groups from acetyl-CoA to specific lysine residues on the N-terminal tail of 
nucleosomal core histones. Acetylation of histones results in charge neutralization of lysine 
residues and decreases the affinity between histones and nucleic acids, and leads to relaxed open 
chromatin structures.84 Tip60 is recruited by many key transcription factors to the chromatin 
template and aberrant Tip60 activity is involved in several types of human diseases such as 
neurodegeneration and cancer.36, 90, 154 In the pathogenesis of Alzheimer’s disease, the 
intracellular C-terminal part of β-amyloid precursor protein (APP) associates with the APP-
binding protein Fe65 and Tip60, leading to apoptosis and downstream gene activation in parallel 
with the pathway of the amyloid β-peptide release.112, 155 Research has shown that Tip60 is 
intimately linked to oncogenesis.88, 107 Oncogenic transcription factors including c-Myc,41 E2F,97 
and nuclear factor-κB98, 156, 157 associate with and are coactivated by Tip60. Tip60 level is 
substantially high and contributes to the abnormal HAT activity in ODC/Raps tumors.110, 111 In 
prostate cancer, Tip60 is involved in the progression to the androgen-refractory state.116, 117 
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Tip60 is upregulated and predominantly resides in the nucleus of hormone resistant prostate 
cancer cells and tissue specimens from patients who failed endocrine therapy.116 Importantly, in 
hormone resistant prostate cancer cells, Tip60 is constitutively recruited to androgen response 
elements such as prostate-specific antigen (PSA) promoter and enhances PSA expression even in 
the absence of androgen.116 Therefore, upregulation of Tip60 may provide a mechanistic 
explanation why androgen receptor-regulated genes become expressed when the tumor relapses. 
These observations highlight the significance of Tip60 as a potential pharmacological target in 
disease therapy. 
In light of the significance of HAT inhibitors as potential new therapeutics, quite a few 
efforts have been invested on developing small molecule inhibitors of HAT enzymes.91 Most 
inhibitors target robust HATs p300/CBP and PCAF/GCN5.158-162 On the other hand, inhibitors of 
the class of MYST HATs are rarely reported. Balasubramanyam et al47 reported a naturally 
occurring HAT inhibitor, anacardic acid, from cashew nut shell liquid. It works as weak 
nonspecific inhibitors of p300/CBP (CREB-binding protein), and PCAF (p300/CBP-associated 
factor), and MYST HAT Tip60, and is capable of easily permeating the cells in culture. 
Curcumin (diferuloylmethane), an ingredient from the plant Curcuma longa rhizome, was 
reported to inhibit the HAT activity in general.61 Both curcumin and anacardic acid have been 
shown to have many non-HAT targets.  For example, Shankar et al163 showed that curcumin 
induces apoptosis in prostate cancer cells through activation of multiple signaling pathways, 
including induction of expression of proapoptotic proteins Bax, Bak, PUMA, Noxa, and Bim, 
and inhibition of expression of antiapoptotic proteins Bcl-2 and Bcl-XL. Anacardic acid was 
previously demonstrated as an inhibitor of DNA polymerase.33 To develop inhibitors more 
specifically targeting the MYST family of HATs, our group recently reported substrate-based 
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analog compounds for Tip60 inhibition.147 Although they present good inhibition activities, the 
negative charges due to the presence of CoA motif imply that this type of inhibitors may have 
low pharmacokinetic performance in vivo.142 To further develop potent inhibitors of MYST 
HATs with enhanced pharmacological properties, in this work, we have conducted a virtual 
screening based on the crystal structure of Esa1 (the yeast homolog of Tip60) to search for small 
molecule inhibitors. In combination with biochemical inhibition studies, several micromolar 
inhibitors are discovered. 
4.2. Results and Discussion 
4.2.1. Virtual screening  
Potent small molecule inhibitors are of great value as chemical probes for interrogating 
cellular functions of biological targets. Tip60 is an important MYST HAT and engaged in 
multiple cellular pathways.36 However, there is no report on specific inhibitors of Tip60 so far. 
We performed a virtual screening with the attempt to search for Tip60 inhibitors from the 
ChemBridge small molecule collection (about half million compounds) based on the reported 
crystal structure of Esa1 (the yeast homolog of Tip60).30, 164 In the virtual screening scheme, the 
2D structures of each of these organic molecules are converted into 3D structures and assigned 
atomic charges with the AM1-BCC protocol.165, 166 Then the molecular docking program, 
DOCK6.1, is used to perform the initial high-throughput virtual screening of these compounds in 
binding to Esa1.167-169 Residues within a radius of 6 Å around the center of CoA binding in the 
Esa1 structure were defined as the active site to construct a grid for the virtual screening. After 
collecting the top hits, a re-analysis of the initial hits, including drug-like properties,170 consensus 
scoring evaluation,171 absorption, distribution, metabolism, excretion and toxicity (ADMET) 
prediction,172 hydrogen bond, and hydrophobic profiles and binding orientation examination, was 
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performed. From the virtual screening and analysis, 76 top hits were selected and subjected to 
experimental tests for their ability to inhibit the HAT activity of Tip60 (Figure 4.1). 
 
Figure 4.1. Docking conformations of the 76 virtual hits (blue sticks)) around the binding 
site (green box) of ESA1 (pink ribbons). 
 
4.2.2. Biochemical tests of the virtual screen hits  
To evaluate the activities of the 76 virtual screen hits for Tip60 inhibition, we carried out 
histone acetylation with the classic radioisotope-labeled approach. [14C] acetyl-CoA was used as 
the acetyl donor and a peptide containing the N-terminal twenty amino acid sequence of histone 
H4 (H4-20) was used as the Tip60 substrate. The HAT reaction catalyzed by recombinant Tip60 
was carried out in the presence and absence of individual virtual screen hits to quantitatively 
evaluate their inhibition potency. All the compounds were dissolved in DMSO to make a 5-mM 
stock solution. Because many compounds have poor solubility in the aqueous assay buffer, 
DMSO had to be present in the acetylation assay buffer. There is a concern that DMSO may 
affect the enzymatic activity of Tip60. Thus, we first tested the tolerance of Tip60 towards 
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different concentrations of DMSO. As can be seen from Figure 4.2, in the range of 0—20% 
DMSO (v/v), there is almost no effects observed on Tip60 activity. Even at 30% of DMSO, the 
retained activity of Tip60 is still 90%. The IC50 of DSMO from this test is 37%. We found that in 
the presence of 10% DMSO in the assay buffer the individual hit compounds were completely 
dissolved at 100-μM level. Under this condition, the influence of DMSO on Tip60 activity is 
negligible. 
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Figure 4.2. Characterization of chemical inhibition of Tip60 activity. (a) Effect of DMSO on 
the enzymatic activity of Tip60. (b) Effect of compound a on the enzymatic activity of 
Tip60. The reactions contain 100 μM of H4-20 and 10 μM of [14C] acetyl-CoA. 
A typical inhibition screen assay was carried out with a reaction mixture containing 0.1 
μM of recombinant Tip60, 10 μM of [14C]-labeled acetyl-CoA, 100 μM of H4-20, and 100 μM 
of individual compounds. The retained fractional activity of Tip60, namely the enzymatic 
activity in the presence of a hit divided by that in the absence of the hit, was used to 
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quantitatively evaluate the potency of hit compounds. It is notable to mention that, for all the 
enzymatic assays, the acetylation reaction is maintained under initial condition so that the 
reaction yields of the limiting substrates are lower than 10%, which is to ensure that the 
concentrations of acetyl-CoA and the peptide substrate remained constant over the time course of 
acetylation reaction. Identified hits can be further characterized by its IC50 value. For IC50 
measurement, the activity of Tip60 was measured at varied concentrations of inhibitor, and IC50 
value is defined as the inhibitor concentration at which 50% of enzyme activity was blocked. A 
typical IC50 measurement titration curve was shown in Figure 4b. From the experimental tests, 
we found two compounds that possess inhibition activities, i.e. a and b (Figure 4.3). Their IC50 
values are 149 μM and 181 μM, respectively. In order to look for analogous potent inhibitors, we 
performed similarity search on the ChemBridge database and selected 29 additional compounds 
that bear structural similarities to compound a and b. The inhibition activities of these 
compounds toward Tip60 were also analyzed using the radioactive biochemical assay. From this 
study, two more inhibitors were found, i.e., c and d (Figure 4.3). These two compounds are 
structural analogs of compound a, confirming that the core structure in the three compounds is a 
valid structural framework for Tip60 inhibition. For the analogs of compound b, we did not 
identify additional inhibitors. The inhibition data of the four inhibitors are listed in Table 4.1. 
We compared the activities of the four discovered inhibitors with curcumin, a natural 
product which was reported as a generic HAT inhibitor.61, 173 The data showed that inhibitors a, 
b and d are more potent than curcumin and compound c has similar activity as curcumin (Figure 
4.4). Furthermore, we examined whether the inhibition by these new compounds was specific for 
Tip60. Thus, we tested the inhibition by compound a on several other HAT enzymes, i.e. Esa1, 
p300, and PCAF. p300 and PCAF belong to different HAT families. Esa1 and Tip60 are both 
52 
 
 
MYST members. H4-20 was used as substrate for Esa1 and p300 as well. For PCAF catalysis, 
the histone H3 N-terminal 20-aa tail peptide (i.e., H3-20) was used. The data are listed in Table 
4.2 and show that compound a inhibits all the tested HAT enzymes at similar levels, implicating 
that the inhibition is not specific for MYST HATs. A computational study (see the next) offers 
structural insight about the nonspecific inhibition by these inhibitors. 
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Figure 4.3. Structures of the identified Tip60 inhibitors. 
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Figure 4.4. Inhibition of Tip60 by the identified inhibitors and curcumin at 250 μM. The 
reaction mixture contains 100 μM of H4-20, 10 μM of [14C] acetyl-CoA, and 200 nM of 
Tip60. The reaction time is 10 min. 
4.2.3. Inhibition model of the discovered inhibitors.  
To understand the mechanism by which the discovered small molecule inhibitors block 
the activity of Tip60, we performed a docking study of compounds a and b with the recently 
disclosed crystal structure of Tip60 protein (PDB ID 2OU2) (Figure 4.5). Briefly, the 3-
dimensional structures of compounds a and b were constructed in Maestro9.0.211. The Tip60 
structure file was modified in Maestro9.0.211 to add hydrogen atoms and remove water 
molecules. Acetyl-CoA ligand was also removed from tip60 to create a binding pocket. Docking 
of the compounds into Tip60 was made with AutoDockTools4.2. Structural analysis with 
PyMOL was performed following the docking process. As shown in Figure 5, the results reveal 
that the docked poses of both compounds a and b superimpose well with the original acetyl-CoA 
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binding ligand in the crystal structure. Thus, the docking data strongly support that compounds a 
and b target the acetyl-CoA binding site of Tip60. The competition between the inhibitors and 
acetyl-CoA was verified by experimental assays. The first experimental evidence comes from the 
fact that the IC50 of these compounds vary with the concentration of acetyl-CoA. For example, at 
10 μM of acetyl-CoA, IC50 of inhibitor a was 149 μM (Table 4.1), but at 1 μM of acetyl-CoA, it 
decreased to 87 μM (Figure 4.6). To further validate the results of competitive nature of 
inhibition, we conducted steady-state kinetic characterization. The initial velocities of Tip60 
were measured at several selected concentrations of inhibitor a over a range of varied 
concentrations of acetyl-CoA while fixing the concentration of the peptide substrate. The data 
were plotted in the Michaelis-Menten format with velocity versus concentration of acetyl-CoA 
and in the double reciprocal format with 1/velocity versus 1/(concentration of acetyl-CoA) 
(Figure 4.7). As can be seen from the double-reciprocal plot, a series of straight lines intersected 
on the left side of the ordinate, a feature characteristic of noncompetitive inhibition. Together 
with the result of the docking study, we suggest that the binding site of inhibitor a partially 
overlaps with the acetyl-CoA binding site in Tip60. Future work is needed to optimize structures 
of the chemical hits to obtain inhibitors with improved potency and specificity for Tip60. 
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 (a) 
 
(b) 
 
Figure 4.5. Docking of inhibitors a and b in the crystal structure of Tip60 (PDB: 2OU2). 
Both compounds target to the acetyl-CoA binding pocket and interact extensively with 
residues in the pocket. 
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Figure 4.6. Inhibition of Tip60 by Compound a 
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Figure 4.7. Steady-state kinetic analysis showing that inhibitor a competes with AcCoA. (a) 
The Michaelis-Menten data of Tip60 activity at different concentrations of 14AcCoA in 
the presence of three selected concentrations of compound a (♦0 μM, ♦80 μM, ▲150 
μM). (b) The reciprocal LB plot of the Michaelis-Menten data. 
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Table 4.1. IC50 of the identified Tip60 inhibitors. Experimental condition was H4-20, 100 
μM; [14C] acetyl-CoA, 10 μM; Tip60, 200 nM; and reaction time was 10 min. 
Inhibitors IC50  (μM) 
a 149 ± 36 
b 181 ± 60 
c 400 ± 30 
d 240 ± 15 
 
Table 4.2. Comparison of the inhibition of Tip60, Esa1, p300, and PCAF by compound a. 
Experimental condition: Tip60 concentration was 200 nM and reaction time was 10 min; 
Esa1 concentration was 25 nM and reaction time was 5 min; p300 concentration was 5 nM 
and reaction time was 10 min; PCAF concentration was 5 nM and reaction time was 3.5 
min. 10% DMSO was present in Tip60, Esa1 and p300 assay, and 2% DMSO was present 
in PCAF assay. 
  Tip60 Esa1 p300 PCAF 
H4-20/H3-20 (μM) 100 100 100 100 
Acetyl-CoA (μM) 10 10 10 10 
IC50 (μM)  149 190 150 >100 
 
4.3. Conclusion 
Tip60 is an important protein target for chromatin remodeling and is involved in multiple 
cellular processes. Inhibitors of Tip60 have great value as chemical genetics tools for 
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interrogating the function of Tip60 in different pathways and are also potential therapeutic 
agents. We discovered several micromolar inhibitors of Tip60 from high-throughput virtual 
screen in combination with experimental inhibition studies. Docking studies and kinetic analyses 
showed that these new inhibitors partially target the cofactor-binding site in Tip60. This work 
provides valuable structural scaffolds for further development of potent inhibitors of Tip60 and 
the MYST family of HATs. 
4.4. Experimental 
4.4.1. Materials  
Small molecule compounds were purchased from ChemBridge Corporation. Peptides 
were synthesized using Fmoc-based solid phase methodology. Fmoc-protected amino acids and 
solid phase resins were purchased from NovaBiochem. [14C]-labeled acetyl-CoA was purchased 
from Perkin Elmer. Tip60 recombinant protein was expressed as previously described.147 
4.4.2. Virtual screening  
Docking-based virtual screening was conducted by following similar procedures reported 
earlier.14 Compounds from the ChemBridge database were converted into 3D structures using the 
CONCORD program.174 The 3D structures of the compounds had hydrogen atoms added and 
were assigned AM1-BCC partial charges.165, 166, 175 Esa1 crystal structure (PDB entry: 1FY7)164 
was added hydrogen atoms and then assigned Kollman-all charges with the SYBYL 7.1 
program. Residues within a radius of 6 Å around the center of the CoA binding in the Esa1 
structure were defined as the active site to construct a grid for the virtual screening. The position 
and conformation of each compound were minimized by the anchor fragment orientation as well 
as by the torsion minimization method implemented in the DOCK 6.0 program.176 Fifty 
conformations and a maximum of 100 anchor orientations for each compound were generated, 
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and the binding energy of all the docked conformations were minimized by 100 iterations using 
the standard approach as described in the literature.176 The docked molecules were ranked based 
on the sum of the van der Waals contacts and electrostatic energies to obtain the top 1000 
compounds. After collecting the top hits, re-analysis of virtual screening results was conducted 
using drug-like property criteria170 by the FILTER 2.0.1 software.177 We then performed 
consensus scoring evaluation171 by ChemScore,178, 179 PLP,180 ScreenScore,181 ChemGauss and 
ShapeGauss182 implemented in the FRED 2.2.3 software,177 as well as hydrogen bond and 
hydrophobic profiles checked by the IDEA 8.8 software,183 As the final step, a manual binding 
orientation and conformational analysis was performed to come up with the final 76 hits for 
biological evaluation (Figure 4.1). 
4.4.3. Radioactive HAT inhibition assay  
Radioisotope-labeled HAT assay was carried out at 30 °C in a reaction volume of 30 μL. 
The reaction buffer contained 50 mM HEPES (pH 8.0), 0.1 mM EDTA, 50 μg/mL BSA, 10% 
DMSO, and 1 mM dithiothreitol (DTT). Typically, [14C] acetyl-CoA was used as the acetyl 
donor and a peptide containing the N-terminal 20-amino acid sequence of histone H4, namely 
H4-20, was used as the HAT substrate. The reaction was initiated with the HAT enzyme after the 
other components (acetyl-CoA, H4-20, and inhibitor) were equilibrated at 30 °C for 5 min. Rate 
measurements were based on initial conditions (generally less than 10% consumption of the 
limiting substrate). After the reaction, the mixture was loaded onto a Waterman P81 filter paper, 
dried 30 min, and then washed with 50 mM of sodium bicarbonate (pH 9.0) for two times (10 
min each). The paper was air-dried and the amount of radioactivity incorporated into the peptide 
substrate was quantified by liquid scintillation. For kinetic inhibition pattern analysis of 
compound a, initial velocities of Tip60 were measured at a range of varied concentrations of 
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AcCoA, a fixed concentration of H4-20 (100 μM), and selected concentrations of inhibitor a, 
i.e., 0 μM, 80 μM, and 150 μM. The data were displayed in both Michaelis–Menten and 
Lineweaver–Burk plots. In all cases, background acetylation (in the absence of enzyme) was 
subtracted from the total signals. All the assays were performed at least twice, and duplicates 
generally agreed within 20%. 
4.4.4. Docking study of the identified hits  
For ligand-protein docking, the 3-dimensional structures of hit compounds were 
constructed in Maestro9.0.211. The Tip60 PDB file was modified in Maestro9.0.211 to add 
hydrogen atoms and remove water molecules and the acetyl-CoA from tip60. AutoDockTools4.2 
was employed to dock the compounds into Tip60. PDBQT files were generated in 
AutoDockTools for both of the ligand and the macromolecule for docking. AutoGrid was used to 
generate a grid box for docking process. AutoDock was then used to dock selected hits 
individually into Tip60. The Genetic Algorithm with 2,500,000 maximum numbers of evals and 
50 generations for picking individuals were used as the docking parameters. Structural analysis 
with PyMOL was performed following the docking process. 
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CHAPTER 5 
Anacardic acid derivatives as inhibitors of Tip60 
5.1. Introduction 
Anacardic acid (6-pentadecylsalicylic acid) (AA) (Figure 5.1), a natural product from the 
traditional medicinal plant cashew nut shell liquid,184 has been found to have important 
biological activities, including antitumor activity,185 antioxidant activity,186 and sensitizing tumor 
cells to ionizing radiation.57 It is also reported to act as an effective inhibitor of numerous 
enzymes, such as tyrosinase,187 xanthine oxidase,188 phosphatidylinositol-specfic phospholipase 
C,189 tissue factor VIIa,190 cyclooxygenase (COX),191 lipoxygenase,14 and histone 
acetyltransferases (HATs).47, 57, 147, 192, 193 
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Figure 5.1. The chemical structures of anacardic acid and AcCoA 
In HAT inhibition study, AA and its derivatives have been discovered to be potent 
modulators for p300 and p300/CBP-associated factor and strongly effected HAT-dependent 
transcription from a chromatin template.47, 194-196 For example, an amide derivative of anacardic 
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acid was reported as a specific activator of HAT activity of p30047 while AA showed to inhibit 
the HAT activity of p300, PCAF, and the Tip60-dependent activation of ATM in vivo.57 
The modulation mechanism of AA to HATs is poorly understood. The similarity in 
chemical structure between anacardic acid and acetyl-CoA (Figure 5.1) suggested anacardic acid 
might have bonded with the active site (acetyl-CoA binding domain) on the HATs. However, 
Karanam showed a non-competitive pattern for acetyl-CoA vs. AA in p300 inhibition study.47, 57 
Here, starting from the natural product lead HAT inhibitor, AA, we synthesized a series of 
anacardic acid analogs (Table 5.1) and evaluated them for their selectivity and specificity in 
inhibiting histone acetyltransferases, including Tip60, p300 and PCAF. The steady-state kinetic 
analysis of MG149 in the inhibition of Tip60 indicated a competitive pattern for AcCoA and 
non-competitive pattern for H4-20.  
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Table 5.1. Chemical structures of anacardic acid analogs. 
NO. ID Chemical Structure NO. ID Chemical Structure 
1 AW17 
HO
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5.2. Results 
5.2.1. Biochemical tests of the anacardic acid analogs 
Standard HAT filter binding assay was employed to study the selective inhibition of 
Tip60, p300 and PCAF by anacardic acid and its analogs.  H4-derived 20 amino acids and H3-20 
peptide were used as substrates for Tip60, p300, and PCAF. The synthetic method was 
previously described in chapter 2. Our data (Figure 5.2) suggested the inhibitory potency of 
anacardic acid analogs at 200 μM had better ability to inhibit the HAT activity of Tip60 than 
p300 and PACF. At 200 μM level, over 10 compounds showed greater than 50% HAT activity 
inhibition of Tip60. However, at the same condition, no hit was discovered to p300 and PCAF 
other than anacardic acid.  
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The detailed studies of structure-activity relationship for anacardic acid analogs (Tip60) 
are displayed in Figure 5.3. The carboxyl, hydroxyl group and a hydrophobic side chain arranged 
one by one in a benzene ring were found to be effective structures. The inhibition mechanism of 
AA could be explained by the chemical structure similarity between AA and CoA (Figure 5.1). 
The activity of anacardic acid analogs was dramatically lost when the carboxyl group was 
cleaved. The data matched results previously reported in the study of structure activity 
relationship on Lys-CoA.142 The result showed the deletion of phosphate group on the 3' position 
of CoA motif caused the activity of 3'-dephosphate-Lys-CoA was about 33-fold weaker at 
blocking p300 when compared to Lys-CoA.  
Table 5.2 shows the more flexible and lower polarity of the hydrophobic chain allowed 
for increased inhibitory activity. The specificity of Tip60’s inhibitory effect can be enhanced by 
adding one benzyl ring to the side chain of anacardic acid, named MG149.  
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Figure 5.2. Inhibition activities of anacardic acid and its analogs against Tip60, p300, and 
PCAF at 200 μM. The Reaction buffer contains: HEPES pH  8.0 50 mM; EDTA 0.1 mM; 
BSA 50 μg/mL; DTT 1 mM; 2% DMSO; 0.1% Triton-X100. (Tip60: 100 nM; 14AcCoA: 10 
μM; H4-20: 100 μM; reaction time: 10 min at 30 °C) (p300: 5 nM; 14AcCoA: 10 μM; H4-
20: 100 μM; reaction time: 5 min at 30 °C) (PCAF: 5 nM; 14AcCoA: 10 μM; H3-20: 100 
μM; reaction time: 3.5 min at 30 °C) 
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Figure 5.3. The structure-activity relationship (SAR) study of anacardic acid analogs for 
Tip60 
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Table 5.2. IC50 values for #5 (MG149) as an inhibitor of HATs. The reaction buffer: 
HEPES: pH  8.0 50 mM; DTT: 1 mM; BSA: 50 μg/mL; EDTA: 0.1 mM; Triton X100: 
0.1%; DMSO: 2%. 
 
5.2.2. Inhibition pattern of the anacardic acid analog MG149 
Among the synthesized anacardic acid analogs, MG149 was chosen to explore the 
mechanism of inhibition for Tip60. The results indicate (Figure 5.4, 5.5) that inhibition of Tip60 
was competitive with AcCoA and noncompetitive with H4-20.  
Enzymes Reaction Condition AA (μΜ)  MG149  (μΜ) 
Tip60 Tip60: 10 nM,  14AcCoA: 1μM,  
H4-20: 100 μM, Reaction Time: 
7 min, 
64 ± 15 74 ± 20 
 
PCAF PCAF: 1 nM,  14AcCoA: 1μM, 
H3-20: 100 μM, Reaction Time: 
3.5 min, 
> 200 
40 % of activity blocked 
> 200 
5 % of activity blocked 
p300 p300: 5 nM,  14AcCoA: 1μM, 
H4-20: 100 μM, Reaction Time: 
5 min, 
> 200 
40 % of activity blocked 
> 200 
10 % of activity blocked 
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Figure 5.4. Steady-state kinetic analysis of #5(MG149) in the inhibition of Tip60 against 
AcCoA. 0 (red), 80 (blue), and 120 μM (green) of MG149 is used. The reaction condition is 
HEPES: pH 8.0 50 mM, DTT: 1 mM, BSA: 50 μg/mL, EDTA: 0.1 mM, Triton X100: 0.1%, 
DMSO: 2%, Tip60: 50 nM, H4-20: 100 μΜ 
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Figure 5.5. Steady-state kinetic analysis of #5 (MG149) in the inhibition of Tip60 against 
H4-20. 0 (red), 120 (blue), and 150 μM (green) of MG149 is used. The reaction condition is 
HEPES: pH 8.0 50 mM, DTT: 1 mM, BSA: 50 μg/mL, EDTA: 0.1 mM, Triton X100: 0.1%, 
DMSO: 2%, Tip60: 25 nM, AcCoA: 2 μM. 
5.3. Conclusion 
A series of anacardic acid analogs were used to study the inhibition potency of HATs, 
specifically, Tip60, p300 and PCAF. Structure-activity relationship (SAR) indicated that a 
carboxyl group with a flexible and hydrophobic side chain on a phenol ring had the highest 
potential ability to inhibit HAT activity. Among the analogs, MG149 was found to have higher 
specificity inhibitory activity for Tip60 than p300 and PCAF. The inhibition pattern of MG149 
was competitive for AcCoA, and non-competitive for H4-20. 
These preliminary biological data encouraged us to study the effect of select inhibitors on 
the cancer cell study.  
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5.4. Experimental 
5.4.1. Radioactive HAT inhibition assay.  
Radioisotope-labeled HAT assay was carried out at 30°C in a reaction volume of 30 μL. 
The reaction buffer contained 50 mM HEPES (pH 8.0), 0.1 mM EDTA, 50 μg/mL BSA, 10% 
DMSO, 0.1% Triton and 1 mM dithiothreitol (DTT). Typically, [14C] acetyl-CoA was used as 
the acetyl donor and a peptide H4-20 containing the N-terminal 20-amino acid sequence of 
histone H4 was used as the HAT substrate. The reaction was initiated with the HAT enzyme 
after the other components (acetyl-CoA, H4-20, and inhibitor) were equilibrated at 30°C for 5 
min. Rate measurements were based on initial conditions (generally less than 10% consumption 
of the limiting substrate). After the reaction, the mixture was loaded onto a Waterman P81 filter 
paper, dried 30 min, and then washed twice for 10 min with 50 mM of sodium bicarbonate (pH 
9.0). The paper was then air-dried and the amount of radioactivity incorporated into the peptide 
substrate quantified by liquid scintillation.  
For kinetic inhibition pattern analysis of MG149, initial velocities of Tip60 were 
measured at a range of varied concentrations of AcCoA or H4-20, a fixed concentration of H4-20 
(100 μM) AcCoA (2 μM), and selected concentrations of MG149. The data were displayed in 
both Michaelis–Menten and Lineweaver–Burk plots. In all cases, background acetylation (in the 
absence of enzyme) was subtracted from the total signals. All the assays were performed at least 
twice, and duplicates generally agreed within 20%.  
 
 
 
 
72 
 
 
CHAPTER 6 
Fluorescent Reporters of the Histone Acetyltransferase 
(This work is mainly based on the published paper, Anal. Biochem. 380 (2008) 106-110) 
6.1. Introduction 
In the last decade, histone modifications have been established as a critical mechanism 
in the regulation of chromatin remodeling and gene function.8, 77, 197 Among different histone 
modifying enzymes, histone acetyltransferases (HATs) particularly catalyze the transfer of the 
acetyl group from acetyl-coenzyme A (AcCoA) to the ε-amino group of lysine residues in a 
histone or non-histone protein substrate. Lysine acetylation destabilizes the nucleosome 
structure and promotes the accessibility of transcription factors to a genetic locus. In 
agreement with this notion, acetylated chromatin has been associated with transcriptionally 
activated states.82, 84 HATs are classified into several families based on sequence similarity 
and functional correlations.80 These include the p300/CBP family, the GNAT superfamily 
(Gcn5-related N-acetyltransferase; e.g. Gcn5, PCAF; Hat1, Elp3, Hpa2); nuclear receptor 
coactivators like SRC-1, ACTR, TIF2; and the MYST family of proteins (named after its 
founding members, which include MOZ, YBF2/SAS3, SAS2, and Tip60).80-83 Thus far, a 
wealth of cellular and clinical data show that HAT activities are deregulated in many types of 
tumors.81, 87 For example, expression of p300/CBP decreases during chemical 
hepatocarcinogenesis and mutations in p300/CBP are associated with different cancers and 
other diseases.198 In acute myeloid leukemia, the CBP gene is translocated and fused to either 
MOZ and MORF or to MLL gene.199 The expression level of the MYST member Tip60 (the 
human homologue of Esa1) is upregulated in hormone-resistant prostate cancer.116 All of 
these data point toward the pharmacologic relevance of the agents that target this type of 
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epigenetic enzymes. Indeed, quite significant research endeavors in recent years have been 
devoted to designing and discovering chemical HAT regulators.10, 91, 92 
To better characterize the enzymatic functions of HATs as well as to facilitate the effort 
for screening new HAT inhibitors, appropriate assay systems are needed that ideally would 
combine sensitivity, speed, simplicity and cost-effectiveness in order to be suited for rapid and 
high throughput.200, 201 Several HAT assay methods have been described.202-204 The most 
commonly used assays for the in vitro measurement of HAT activities are based on radioisotope 
labeled cofactor AcCoA. Radioisotopic assays suffer from issues of expensive cost of radioactive 
materials, safety of handling radioactivity, and kinetic inflexibility (i.e. endpoint assay). 
Therefore, nonradioactive strategies have been proposed for HAT enzymatic studies.202 These 
methods rely on thiol quantification of the side product coenzyme A (CoASH) to determine the 
HAT activity. In one example, the HAT reaction is coupled with an enzyme (pyruvate 
dehydrogenase or a-ketoglutarate dehydrogenase) that catalyzes the reaction of pyruvate with 
CoASH and reduces NAD+ to NADH.73 Alternatively, the HAT reaction is coupled with thiol 
reactive chemicals such as CPM72 and DTNB.32 In general, these coupled reaction systems 
exhibit reduced sensitivity in comparison to isotopic method and contain more components than 
a pure HAT assay which adds extra complexity. The assay conditions should be thoroughly 
optimized to ensure that the coupled reaction rate does not limit the HAT reaction.202 
We describe here a novel fluorescence strategy for the homogeneous, continuous, one-
step measurement of HAT activity. The principle underlying the fluorescent detection of the 
HAT reaction is based on the fact that acetylation of the ε-amino group of lysine residues 
changes the local microenvironment of the histone peptide from a charged state to a neutral 
state (Figure 6.1). The lipophilicity and steric hindrance at the ε-amino group also increase 
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upon acetylation. If an environmentally sensitive fluorophore is suitably attached to the histone 
peptide, then the photophysical properties of the fluorophore could be affected by the changes 
caused by the acetylation event. In this work, we have used 5-(dimethylamino)-naphthalene-1-
sulfonamide (dansyl, Dns) and fluorescein (FL) as detecting probes. These sensitive fluorophores 
have been previously used to make different molecular sensors.205, 206 
 
Figure 6.1. The principle for the design of the fluorescent HAT reporters 
 
6.2. Results and discussion 
As a proof of concept, we designed the fluorescent HAT reporters based on the N-
terminal twenty amino acid sequence of wild-type histone H4 (wt-H4-20).207 Histone H4 is a 
substrate of a number of HAT enzymes, such as p300/CBP, Esa1 and Tip60.81 In our design, the 
leucine residue at position 10 in the wide type H4 is replaced by lysine or 2,3-
diaminopropionic acid (Dpr) which contains a side chain amino group that can be used for 
selective fluorophore labeling (compounds 2—5 in Figure 6.2). These fluorescent compounds 
were prepared using the Fmoc-based solid phase peptide synthesis strategy. 
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Figure 6.2. Structures of the fluorescent reporters. The red K highlights the lysine residues 
that can be acetylated by HAT p300. 
Two critical challenges need to be addressed for our designed reporters. First, are the 
peptides, after the fluorophore attachment, still good substrates of HATs? Second, do the 
fluorescence signals change upon acetylation? To determine if HATs can acetylate the 
fluorescent H4 peptides, we performed the classical radioactive assay. In this assay, the 
cofactor AcCoA is [14C]-labeled. In the HAT reaction, the radioactive acetyl group is 
transferred to the peptide substrate. As seen in Table 1, all the kinetic parameters Km, kcat, and 
V/K of the four fluorescent peptides are within two fold range compared to those of wt-H4-20 
in the p300 catalysis. This demonstrates that the fluorescent groups on the H4 substrate are 
well tolerated by the HAT p300 enzyme. Interesting, Dansyl labelling of the H4 peptide 
renders it an even better substrate of p300. 
To further confirm that the fluorescent reporters are effective substrates of HATs, we 
measured the mass spectroscopic data of the HAT reaction mixture in which a radioisotope-
free AcCoA was used as the cofactor (Figure 6.3). Very clearly, all the four compounds were 
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efficiently acetylated by p300. This is in agreement with a previous study showing that p300 
can acetylate three to four lysines on H4 at its N-terminus.94 Thus, the added fluorophores 
have little interference with the substrate recognition by p300. 
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Figure 6.3. Mass spectroscopic data for peptides. The result shows every peptide was 
acetylated by p300. The number of acetyl group can be read in the mass. 
After having confirmed that the fluorescent compounds are effective HAT substrates, 
we next examined their fluorescence response in the presence of p300 and radioisotope-free 
AcCoA. The excitation wavelength was 330 nm for dansyl-labeled peptides and 498 nm for 
fluorescein-labeled peptides, respectively. As expected, different reporters exhibited varying 
degrees of fluorescence intensity change upon acetylation (Figure 6.4). After 30 min of 
reaction, the fluorescence intensity of H4-Dpr-Dns and H4-Lys-Dns (maximum emission at 
about 556 nm) increased by 24%, and 19%, respectively. The intensity increase for H4-Dpr-
FL and H4-Lys-FL (emission maximum at 523 nm) is 11% and 18%, respectively. The 
enhancement of fluorescence intensity indicates that the microenvironment around the 
fluorophores is modulated by the added acetyl groups. Such microenvironmental changes may 
include enhanced hydrophobicity and variation in local pH. Although the intensity changes 
upon the HAT reaction are not particularly exceptional in terms of screening applications, this 
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is the first proof-of-concept that such a simple, one-step strategy works well to directly 
produce fluorescent readouts from histone acetylation. 
Several interesting comments can be drawn from these fluorescence data. First, the 
dansyl presents a larger fluorescence response than fluorescein. This may not be surprising 
because dansyl is usually considered more sensitive than fluorescein to microenvironment 
factors such as polarity, charges, solvent exposure.208 In addition, a small blue shift was 
observed when the dansyl-labeled peptides were acetylated, which further supports the notion 
that the microenvironment surrounding the fluorophore became more hydrophobic after the 
acetylation process (Figure 6.4).182, 14 Second, the length of side chain through which the 
fluorophore is linked to the H4 peptide backbone does not show apparent impact on 
fluorescence response. This largely reflects that the acetylation affects the emission of the 
fluorophores in a robust manner. Third, importantly, when the product feedback HAT 
inhibitor, CoASH, is present, the fluorescence intensity is reduced to a level close to the one 
without the HAT p300 (Figure 6.4). This indicates that the fluorescence intensity corresponds 
well to the acetylation and gives evidence that the fluorescence measurement is suitable for 
chemical inhibition analysis. Compared to existing non-radioactive methods, which involve 
additional coupling enzymes or reagents,72, 73 our fluorescent reporter HAT assay is simply a 
mix-and-measure procedure. Thus, this method provides clean signals without much 
complication and minimizes pitfalls of false positives when used in a drug-screening mode. 
Furthermore, the emission difference of the fluorescent H4 peptides between the unacetylated 
and acetylated forms indicates that the latter could be potentially used to set up a new-type 
fluorescence-based histone deacetylase (HDAC) assay. 
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Figure 6.4. The fluorescence intensity of peptides (Green: peptide/p300/AcCoA; black: 
peptide/p300/AcCoA/CoASH; Blue: peptide and AcCoA) after 30min acetylation 
reaction, H4-Dpr-Dns and H4-Lys-Dns (excitation at 330nm; maximum emission at 
550 nm; slit: 3, 5) increased by 20%, and 21%, respectively. The intensity increase for 
H4-Dpr-FL and H4-Lys-FL (excitation at 498 nm; emission maximum 523 nm; silt: 1, 
1) is 30% and 9%. 
We also measured the time-course curves of the fluorescence intensity in order to 
monitor the HAT reaction progress. As seen in Figure 6.5, the fluorescence signals gradually 
increase with the reaction time. The fluorescence response to reaction time is neither linear 
nor single exponential. This is most likely because the acetylation of the H4 peptide by p300 
is a heterogeneous process and the sensitivity of the fluorophore to each acetyl-Lys is also 
different. The kinetic data give further evidence that the fluorescence changes are due to the 
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gradual acetylation of the reporters by the HAT enzyme. Again, the acetylation process is 
strongly blocked by the HAT inhibitor CoASH. 
 
Figure 6.5. Time course curve of the fluorescence intensity of H4-Dpr-Dns and H4-Lys-Dns 
(λex = 330 nm, λem = 556 nm) in the acetylation reaction catalyzed by p300, in the absence 
(a) and presence (b) of 100 μM CoASH inhibitor. Curve c is the control (without p300). 
Table 6.1. p300 steady-state kinetic parameters for H4-20 and fluorescent peptides. 
 Km  (μM) kcat (s-1) V/K (M-1 s-1) 
wt-H4-20 4.01 ± 1.09 1.82 ± 0.23 4.6 × 105 
H4-Dpr-Dns 1.88 ± 0.43 1.61 ± 0.11 8.5× 105 
H4-Lys-Dns 3.19 ± 0.42 2.40 ± 0.11 7.5× 105 
H4-Dpr-FL 7.44 ± 2.79 2.10 ± 0.34 2.9× 105 
H4-Lys-FL 3.70 ± 1.53 1.06 ± 0.16 2.9× 105 
 
6.3. Conclusion 
Taken together, we have presented the design, synthesis and evaluation of a series of 
novel peptide-based HAT reporters that allow for monitoring HAT activity via sensitive 
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fluorescence detection. The fluorescent sensing is continuous, homogeneous, and 
nonradioactive. Thus this strategy should be widely useful for assaying HAT activity in vitro 
as well as for the discovery of HAT modulators. 
6.4. Experimental 
6.4.1. Synthesis of the fluorescent reporters 
Solid Phase peptide synthesis (SPPS) was performed on a PS3 peptide synthesizer 
using the Fmoc [N-(9-fluorenyl) methoxycarbonyl] strategy. For the coupling of each amino 
acid (AA), 4 eq. of AA/HBTU/HOBt (N-Hydroxybenzotriazole) were used. Removal of Fmoc 
was performed with 20% v/v piperidine/DMF. The N-terminal amino groups were acetylated 
with Ac2O. After all the amino acids were coupled to the solid phase, the Dde or ivDde group 
was removed with 2% hydrazine in DMF. For dansyl labelling, the resin was treated with 1 
equivalent of dansyl chloride and 10 equivalents of pyridine in DMF for 2 h. To label with 
fluorescein, the resin was reacted with 4 equivalents of fluorescein-NHS and 10 equivalents of 
pyridine in DMF for 4 h. Peptides were cleaved from the resin by treatment with 95% TFA, 
2.5% H2O and 2.5% triisopropylsilane for 4 h. Crude products were precipitated with cold 
ether, and then purified with reverse-phased HPLC. The final products were characterized 
with analytical HPLC and MALDI-MS. 
6.4.2. HAT assay 
Recombinant p300 HAT domain (1287-1666) was a gift from Dr. Philip Cole at Johns 
Hopkins University. Its expression has been described in an earlier report.32 The HAT 
reaction buffer contained 50 mM Tris-HCl, pH 7.4, 1 mM DTT, 0.1 mM EDTA, 150 mM 
NaCl, and 50 μg/mL bovine serum albumin. Radioisotope labelled assay was carried out at 30 
°C in a reaction volume of 30 μL. The concentration of [14C]-acetyl-CoA (GE Healthcare) is 
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10 μM. The enzyme concentration is 5 nM for p300. Reactions were initiated with the enzyme 
after the other components were equilibrated at 30 °C for 5 min. After 3.5 min of reaction, the 
mixture was directly loaded onto Waterman P81 filter paper and then washed with 50 mM of 
sodium bicarbonate (pH 9.0) for three times. The radioactive products were quantified by 
liquid scintillation. For MS analysis, reaction mixtures were prepared containing 10 μM of 
non-radioactive AcCoA, 1 μM of peptide and 0.1 μM of p300. The reaction mixtures were 
incubated at 30 °C for 30 min. After incubation, TFA was added to each sample with a final 
concentration of 1% (v/v). The samples were then directly subjected to MALDI-MS analysis. 
For the fluorescent HAT assay of each of the four reporters, several samples were made 
and tested (Figure 6.4): (a) 10 μM of AcCoA and 1 μM of fluorescent reporter, (b) 10 μM of 
AcCoA, 1 μM of fluorescent reporter, 0.1 μM of p300, and (c) 10 μM of AcCoA, 1 μM of 
fluorescent reporter, 0.1 μM of p300, and 100 μM of CoASH.  The reaction mixture was first 
made on ice and then was immediately incubated at 30 °C for 30 min before fluorescence 
measurement.  To measure the kinetic curves (Figure 6.5), the HAT reaction mixtures were 
prepared as followed: (a) 10 μM AcCoA and1 μM of peptide, (b) 10 μM AcCoA, 1 μM of 
peptide (H4-Lys-Dns or H4-Dpr-Dns), and 0.25 μM p300, and (c) 10 μM AcCoA, 1 μM of 
peptide (H4-Lys-Dns or H4-Dpr-Dns), 0.25 μM p300, and 100 μM CoASH. The assays were 
carried out in a 1-mL quartz cuvette at 30 °C. The excitation and emission wavelengths were 
330 nm and 556 nm, respectively. All the fluorescence measurements were done on a 
Fluoromax-4 instrument (Horiba Jobin Yvon). 
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CHAPTER 7 
Summary 
Tip60 is a member of the MYST family, and has been found to play prominent roles in 
several types of human diseases, suggesting that Tip60 may be a potential pharmacological target 
in disease therapy. To discover potent inhibitors of MYST HATs, we explored three strategies to 
develop inhibitors of Tip60.  
1. Bisubstrate analogs were designed and synthesized for the inhibition of Tip60. In 
particular, H4K16CoA was determined as one of the most potent inhibitors for Tip60, and the 
inhibition is competitive versus acetyl-CoA and noncompetitive versus the histone H4 substrate. 
Based on SAR study, we found little effect due to increased peptide length of histone H4 
bisubstrate analogs upon Tip60 inhibition. We also found adenosine pyrophosphate to be 
essential for the inhibitory activity of these compounds.  
The negatively charged phosphate groups in the CoA motif cause poor pharmacokinetics 
performance and restrict their applications in vivo. To overcome this problem, we synthesized 
histone peptide K-pantetheine analogs using a concise method. The overall potencies these 
compounds have are much weaker than the peptide-CoA. However, the pantetheine was shown 
to exhibit good ability of penetrating the cell membrane and can be transformed to CoA by the 
endogenous CoA metabolic pathway. This advantage indicates that the peptide-pantetheine 
analogs may form the peptide-CoA products by biosynthesis and be converted to potent 
inhibitors of HATs in the cell.  
In the future work, these synthesized bisubstrate inhibitors can be used for co-
crystallization with HATs of the MYST family, especially Tip60. It is needed to obtain more 
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binding information between Tip60 and the two substrates to explain the catalytic mechanism of 
MYST family. Further, an important and urgent question to be answered is how to deliver the 
bisubstrate inhibitors to cell. Since we have already obtained the peptide-pantetheine analogs, 
future efforts will be applied to HAT inhibition study by peptide-pantetheine analogs in vivo.  
2. Other than bisubstrate inhibitors, small molecule inhibitors of MYST family are rarely 
reported. To develop small molecule inhibitors targeting the MYST family of HATs, we have 
performed virtual screening based on the crystal structure of Esa1 (the yeast homolog of Tip60). 
In combination with the HAT assay and computer-assisted docking, four small molecules are 
discovered as AcCoA-competitive inhibitors of Tip60 at micromolar level. These valuable 
structural scaffolds provide important information for future development of potent inhibitors of 
Tip60 and the MYST family of HATs.  
3. Anacardic acid (6-pentadecylsalicylic acid) was reported as an effective inhibitor of 
several enzymes, such as HATs and tyrosinase. Its unique chemical structure and biological 
functions have interested many chemists and pharmacologists. A series of anacardic acid 
derivatives were designed, synthesized by our collaborator, and evaluated by our lab for HAT 
inhibition. Several compounds were found to be selective for Tip60. Among the 24 derivatives of 
anacardic acid, MG149 was disclosed as an AcCoA-competitive inhibitor of Tip60 by HAT 
assay and may act as a lead compound to develop more potent and selective inhibitors for the 
MYST family of HATs.  
These small molecule inhibitors found in vitro study in our lab during last 5 years lead us 
to apply them in cell-based study (in vivo) in the future. These researches will record the story 
about how these compounds work in the living system. 
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HATs have been reported to play a crucial role in a variety of cellular functions, such as 
gene transcription, differentiation, and proliferation, DNA repair, and chromatin remodeling. To 
better characterize the enzymatic activity of HATs, sensitivity, fast, simplicity and cost-
effectiveness assay systems are needed to be suited for rapid, specificity, and high throughput. 
The common methods usually used for the in vitro measurement of HAT activities are 
radioactive labeled co-factor AcCoA or probes reacted with the free thiol group of product CoA. 
The former one has the disadvantages of cost of radioactive materials and safety of handling, 
while the latter one has the drawback that the reaction system contains more components which 
may affect the HAT assay. Our lab developed a novel HAT assay based on engineering the 
environmentally sensitive fluorophores to the substrate of HATs. The experiment confirmed the 
HAT activity can be detected by this homogeneous, continuous, and one-step assay. However, 
the sensitivity of this method is low and the fluorescence intensity of reporters increased by 
around 20%. This preliminary work encourages us to look for the more sensitive fluorophores 
and the key acetylation sites on the substrates of HATs in the future.  
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APPENDIX 
Table 1. The chemical structure of HAT modulators  
Chemical Name Chemical Structure Chemical Name Chemical Structure 
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Figure 1. SDS-PAGE for HAT enzymes 
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Figure 2. Kinetics of Tip60 involved acetylation reaction 
 
 
Figure 3. Michaelis-Menten curve of Tip60-catalyzed acetylation 
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Figure 4. Scheme of HAT assay  
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Table 2. The 76 compounds selected from virtual screening  
ID numbers Commercial ID Chemical structures Relative activity 
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O
S
N
Br 94 ± 7 
71. JW-71 
5466544 
S
N
O
O
93 ± 6 
98 
 
 
72. JW-72 
5617353 
N
S OH
O
O
O 109 ± 16 
73. JW-73 
5916854 
N
S
O
O
Br Cl
96 ± 9 
74. JW-74 
6203922 
N N
S SO
O
O
O
107 ± 2 
75. JW-75 
6395884 
N
S OH
O
O
O
O
HO
94 ± 2 
76. JW-77 
7954366 
N
S OH
O
O
O
N
H
O
94 ± 6 
77. JW-78 
7971785 
NSO
O
O
O
O 81 ± 15 
78. JW-79 
7975063 
S
N
O
O
OO
80 ± 8 
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Table 3. Analogs of #10 and their relative activity 
ID numbers Commercial 
ID 
Chemical structures Relative activity 
1. JW-10 5601544 
N
NS
N
S
N
O
OO O
 
43 ± 1 
2. JW-81 5522297 
N
N
N
S
N
O
OO2N
82 ± 11 
3. JW-83 5665371 
N
N
N
S
N
O
O
S
F
 
102 ± 1 
4. JW-84 5606013 
N
N
N
S
N
O
O
O
O
HBr
 
84 ± 14 
100 
 
 
5. JW-85 5571918 
N
N
N
S
N
O
O
O2N
F
 
82 ± 1 
6. JW-86 5571664 
N
N
N
S
N
O
O
 
92 ±5 
7. JW-87 5571414 
N
N
N
S
N
O
OO
Cl
O
 
71 ± 7 
8. JW-88 5563158 
N
N
N
S
N
O
O
 
82 ± 6 
9. JW-89 5539619 
N
N
N
S
N
O
OCl
HBr
 
104 ± 2 
101 
 
 
Table 4. Analogs of #76 and their relative activity 
ID numbers Commercial ID Chemical structures Relative activity 
1. JW-76 7141526 
 N N
S
C4H9
S
C4H9
O
O
O
O
65 ± 7 
2. JW-90 5133445 
 
N N
O
O
O
O
103 ± 5 
3. JW-91 5629765 
N N
O
O
O
OCl
97 ± 1 
4. JW-92 6382854 
N N
O
O
O
O
H
N
H
N
O O
 
96 ± 4 
5. JW-93 6383000 
 
N N
O
O
O
O
H
N
H
N
 
90 ± 5 
6. JW-94 6385300 
N N
O
O
O
O
NNO
O
O O
 
89 ± 5 
7. JW-95 6386649 
 
N N
O
O
O
O
H
N
H
N
O O
 
92 ± 7 
102 
 
 
8. JW-96 6393484 
N N
O
O
O
O
NN
 
108 ± 8 
9. JW-97 6406374 
 
N N
O
O
O
O
NN
O
O
O
O
 
98 ± 11 
10. JW-98 6416097 
N N
O
O
O
O
NN
 
103 ± 5 
11. JW-99 6420305 
N N
O
O
O
O
H
N
H
N
 
103 ± 3 
12. JW-
100 6553098  
N N
O
O
O
O
O O
 
113 ± 1 
13. JW-
101 
6633465 
N N
O
O
O
OCl  
99 ± 10 
14. JW-
102 7083003  
N N
O
O
O
O  
95 ± 1 
103 
 
 
15. JW-
103 
5321570 
N
O
O
S
 
104 ± 13 
16. JW-
105 6390824  
N N
O
O
O
O
H
N
H
N NN
 
98 ± 1 
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Mass spectra for peptides 
1. H4-20 
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2. H3-20 
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3. Lys-CoA 
 
 
4. H4 (1-20) K5CoA 
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5. H4 (1-20) K8CoA 
6. H4 (1-20) K12CoA 
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7. H4 (1-20) K16CoA 
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8. H2A (1-20) K5CoA 
 
9. H3K14 (1-20) CoA 
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10. H4 (15-17) K16CoA 
999 1201 1403 1605 1807 2009
Mass (m/z)
2.4E+4
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
4700 Reflector Spec #1 MC[BP = 1223.6, 23909]
12
23
.5
12
24
.5
12
77
.5
12
78
.5
12
25
.5
12
79
.5
10
07
.6
12
26
.5
13
31
.4
11
52
.5
 
11. H4 (14-18) K16CoA 
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12. H4 (11-22) K16CoA 
15:55:37  15:55:37100H2O+0.1%HCOOH
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400
%
0
100
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13. Lys-Pantethine 
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14. H4 (15-17) K16 Pantethine 
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16. H4 (11-22) K16 Pantethine 
11:38:54  11:38:5450%MeOH+0.1%HCOOH
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800
%
0
100
WUJIANG_H4_(11_22)_PANT_ESI_POS_ZHENG_060410  38 (0.711) Sm (SG, 2x3.00); Cm (38:42) TOF MS ES+ 
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17. H4-Dpr-FL  
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18. H4-Dpr-Dns 
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19. H4-Lys-FL 
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20. H4-Lys-Dns 
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21. Acetylation of H4-Dpr-Dns 
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22. Acetylation of H4-Lys-Dns 
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23. Acetylation of H4-Dpr-FL 
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24. Acetylation of H4-Lys-FL 
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